Also treating any other symptoms like anxiety or sleep issues, preventing suicide, restoring their functioning in daily life, and crucially preventing recurrence. Those apply to both acute and maintenance phases.
While we're focusing on meds today, we shouldn't forget non-farmacologic options.
No, absolutely not. Especially for mild to moderate depression, they're very important
like psychotherapy.
Yes. Things like CBT, cognitive behavioral therapy, behavioral activation, interpersonal therapy, often first line for less severe cases. And there are tech options, too, like web-based CBT.
That's useful.
And psycho education is key, too. Just explaining the illness, the treatment, stressing adherence, managing expectations about timelines, it really helps.
Lifestyle stuff, too. exercise, diet,
definitely exercise, yoga, maybe dietary changes, even light therapy for seasonal and sometimes non-seasonal depression. They can all play a role. But yeah, for this deep dive, we're honing in on the pharmacologic side.
Okay, let's dive in then. Pharmacologic choices.
What are the general principles we need to nail down for the PBC?
All right, figure one in the depression source gives a good visual algorithm. First point, the recommendations are generally the same for MDD and persistent depressive disorder.
Okay, that's Simplifies things a bit.
It does. And table 3 is super important. The CANMAC classification. It groups anti-depressants into first, second, and third line agents.
Can you give some examples?
Sure. First line includes many you'll know. Bropion, citoprellopram, fluoxitine, peroxitine, certuline, venlaxine, disbenlax, vioitine,
right? The common ones.
Second line might be things like levasipopran, mocklobomide, kishiopene, the atypical antiscychotic. We'll discuss trazadone. and the TCAs the tricyclic
and third line
generally reserved for the mais like phenoline trrenypermine more specialized use knowing this hierarchy helps guide choices
okay that's a great framework how about starting and adjusting doses
the general idea is to get to a minimum therapeutic dose pretty quickly ideally within the first two weeks
then you adjust over the next say four to six weeks watching response and side effects closely
and managing those side effects
vitally important you need to tell patients upfront what to expect. Look at table 4 for common ones. Reassure them that many side effects lessen within about 2 weeks.
But what if they don't or they're just too much?
Good point. If side effects are really intolerable even after trying dose adjustments, then switching might be needed. Maybe between weeks three and eight. Sometimes switching within the same class is enough.
Makes sense. Now, the source mentioned a big comparison study, a network meta analysis.
Ah, yes, that was interesting. It looked at both effectiveness and tolerability. What were the key findings?
Well, it suggests that agents like amitryptaline, acetylopram, erbotazipene, peroxitine, venlaxine, and vortioitine might be uh a bit more effective overall. Agamelatine too, but it's not available in Canada.
Okay, effectiveness. What about tolerability? Who came out better there?
On the tolerability side, the standouts were agamelatine again, esatalopram, fluoxitine, certuline, and vioitine.
So looking at both acetatelopram and vioitine, seem to hit a sweet spot
potentially. Yes. They seem to offer a good balance of being effective and reasonably well tolerated for many patients based on that analysis. Worth keeping in mind.
Definitely. Now, a really critical point, the potential risk of increased suicidal thinking or behavior,
especially in younger people.
Yes, this is a very serious consideration. It's complex. Some studies suggest SSRIs might reduce suicide risk in older adults, but regulatory agencies have issued warnings about a possible increased risk. particularly in children and young adults, especially early in treatment or when changing doses.
So, close monitoring is essential.
Absolutely essential.
While we're focusing on meds today, we shouldn't forget non-farmacologic options.
No, absolutely not. Especially for mild to moderate depression, they're very important
like psychotherapy.
Yes. Things like CBT, cognitive behavioral therapy, behavioral activation, interpersonal therapy, often first line for less severe cases. And there are tech options, too, like web-based CBT.
That's useful.
And psycho education is key, too. Just explaining the illness, the treatment, stressing adherence, managing expectations about timelines, it really helps.
Lifestyle stuff, too. exercise, diet,
definitely exercise, yoga, maybe dietary changes, even light therapy for seasonal and sometimes non-seasonal depression. They can all play a role. But yeah, for this deep dive, we're honing in on the pharmacologic side.
Okay, let's dive in then. Pharmacologic choices.
What are the general principles we need to nail down for the PBC?
All right, figure one in the depression source gives a good visual algorithm. First point, the recommendations are generally the same for MDD and persistent depressive disorder.
Okay, that's Simplifies things a bit.
It does. And table 3 is super important. The CANMAC classification. It groups anti-depressants into first, second, and third line agents.
Can you give some examples?
Sure. First line includes many you'll know. Bropion, citoprellopram, fluoxitine, peroxitine, certuline, venlaxine, disbenlax, vioitine,
right? The common ones.
Second line might be things like levasipopran, mocklobomide, kishiopene, the atypical antiscychotic. We'll discuss trazadone. and the TCAs the tricyclic
and third line
generally reserved for the mais like phenoline trrenypermine more specialized use knowing this hierarchy helps guide choices
okay that's a great framework how about starting and adjusting doses
the general idea is to get to a minimum therapeutic dose pretty quickly ideally within the first two weeks
then you adjust over the next say four to six weeks watching response and side effects closely
and managing those side effects
vitally important you need to tell patients upfront what to expect. Look at table 4 for common ones. Reassure them that many side effects lessen within about 2 weeks.
But what if they don't or they're just too much?
Good point. If side effects are really intolerable even after trying dose adjustments, then switching might be needed. Maybe between weeks three and eight. Sometimes switching within the same class is enough.
Makes sense. Now, the source mentioned a big comparison study, a network meta analysis.
Ah, yes, that was interesting. It looked at both effectiveness and tolerability. What were the key findings?
Well, it suggests that agents like amitryptaline, acetylopram, erbotazipene, peroxitine, venlaxine, and vortioitine might be uh a bit more effective overall. Agamelatine too, but it's not available in Canada.
Okay, effectiveness. What about tolerability? Who came out better there?
On the tolerability side, the standouts were agamelatine again, esatalopram, fluoxitine, certuline, and vioitine.
So looking at both acetatelopram and vioitine, seem to hit a sweet spot
potentially. Yes. They seem to offer a good balance of being effective and reasonably well tolerated for many patients based on that analysis. Worth keeping in mind.
Definitely. Now, a really critical point, the potential risk of increased suicidal thinking or behavior,
especially in younger people.
Yes, this is a very serious consideration. It's complex. Some studies suggest SSRIs might reduce suicide risk in older adults, but regulatory agencies have issued warnings about a possible increased risk. particularly in children and young adults, especially early in treatment or when changing doses.
So, close monitoring is essential.
Absolutely essential.
You have to watch carefully for any emergence or worsening of suicidal thoughts or behaviors, particularly when starting or adjusting doses in younger individuals. It's a risk that has to be weighed against the significant risk of untreated depression itself.
Okay, really crucial point. Let's move into the specific classes. SSRI's first Selective serotonin reuptake inhibitors often first choice you said
that's right they're usually the go-to first choice why generally good tolerability pretty easy dosing usually once a day and you know cost is often lower than some newer drugs
which ones are available here in Canada
you need to know citilopram escalopreg fluoxitine fluoxamin peroxitine and certillene
okay how do they compare to older drugs like tcas
efficacy wise they're generally considered comparable to the tcas but the side effect profile is quite different
what kind of side effects are common with SSRIs.
You often see GI issues like nausea, maybe diarrhea, CNS effects like anxiety, sometimes insomnia or maybe feeling a bit jittery initially. And uh sexual dysfunction is a big one,
right? And what about that GI bleeding risk?
Yes, that's important. There's a potential increased risk, especially if patients are also taking NSAIS or if they have a history of GI bleeds. Something to screen for.
And the sexual dysfunction that can be a real problem. for adherence, can it?
It really can. And unlike some other side effects that might fade, sexual issues, lower libido, difficulty with orgasm, erectile dysfunction can unfortunately persist for some people throughout treatment.
So if that's a major concern,
then you might lean towards non SSRI options that have a lower risk profile for that specific side effect. Think bipen, mtazipene, mockabomide, perhaps vezadone or vioitine.
Good alternatives to keep in mind. Anything else specific about the SSRIs you mentioned? as cytoalopram earlier,
right? Acetyocram is similar to citylopram, its parent drug, but some data suggests it might have potentially superior efficacy in some comparison
and discontinuation effects stopping suddenly.
Big issue. Most SSRIs except fuoxitine because it has such a long halflife can cause discontinuation symptoms if stopped abruptly.
Fluxine kind of tapers itself.
Exactly. But for the others, like peroxitine especially, stopping suddenly can lead to dizziness, nausea, anxiety, flu-l like feelings. So gradual tapering and monitoring are key when stopping.
Okay, got it. Let's move to the SNRI's serotonin norepinephrine reuptake inhibitors. Venlaxine is a key one here.
Definitely venifaxine primarily hits serotonin at lower doses, but as you increase the dose, say above 150 milligrams a day typically, you get significant norepinephrine reuptake inhibition too, dual action.
Does that make it more effective?
Some studies mainly comparing it to fluoxitine suggest potentially higher remission rates, but it's not universally accepted as superior to all SSRIs.
Any specific side effects to watch for with vinax vaccine?
The main one to be aware of is a potential dose related increase in blood pressure. It's not super common, but more likely at doses over 225 milligrams. So monitoring blood pressure, especially at higher doses, is generally recommended.
Okay. What about other SNRIs? Does Venlaxine?
That's the active metabolite of Venlaxine. It might have slightly fewer drug interactions because of metabolism differences. Efficacy is generally seen as similar and it has shown some use specifically in perry and post-menopausal women with depression.
Common side effects
things like insomnia, maybe drowsiness, dizziness, nausea are pretty common.
And deloxitine.
Delloxitine hits both serotonin and norepinephrine right from the starting dose, usually 60 milligrams daily. It also has indications for things like neuropathic pain and fibromyalgia.
Right. Useful if those conditions coexist.
Exactly. A key point for Delloxitine is its metabolism. It uses the CY P1 A2 enzyme.
Ah, so smoking could affect it.
Precisely.
Okay, really crucial point. Let's move into the specific classes. SSRI's first Selective serotonin reuptake inhibitors often first choice you said
that's right they're usually the go-to first choice why generally good tolerability pretty easy dosing usually once a day and you know cost is often lower than some newer drugs
which ones are available here in Canada
you need to know citilopram escalopreg fluoxitine fluoxamin peroxitine and certillene
okay how do they compare to older drugs like tcas
efficacy wise they're generally considered comparable to the tcas but the side effect profile is quite different
what kind of side effects are common with SSRIs.
You often see GI issues like nausea, maybe diarrhea, CNS effects like anxiety, sometimes insomnia or maybe feeling a bit jittery initially. And uh sexual dysfunction is a big one,
right? And what about that GI bleeding risk?
Yes, that's important. There's a potential increased risk, especially if patients are also taking NSAIS or if they have a history of GI bleeds. Something to screen for.
And the sexual dysfunction that can be a real problem. for adherence, can it?
It really can. And unlike some other side effects that might fade, sexual issues, lower libido, difficulty with orgasm, erectile dysfunction can unfortunately persist for some people throughout treatment.
So if that's a major concern,
then you might lean towards non SSRI options that have a lower risk profile for that specific side effect. Think bipen, mtazipene, mockabomide, perhaps vezadone or vioitine.
Good alternatives to keep in mind. Anything else specific about the SSRIs you mentioned? as cytoalopram earlier,
right? Acetyocram is similar to citylopram, its parent drug, but some data suggests it might have potentially superior efficacy in some comparison
and discontinuation effects stopping suddenly.
Big issue. Most SSRIs except fuoxitine because it has such a long halflife can cause discontinuation symptoms if stopped abruptly.
Fluxine kind of tapers itself.
Exactly. But for the others, like peroxitine especially, stopping suddenly can lead to dizziness, nausea, anxiety, flu-l like feelings. So gradual tapering and monitoring are key when stopping.
Okay, got it. Let's move to the SNRI's serotonin norepinephrine reuptake inhibitors. Venlaxine is a key one here.
Definitely venifaxine primarily hits serotonin at lower doses, but as you increase the dose, say above 150 milligrams a day typically, you get significant norepinephrine reuptake inhibition too, dual action.
Does that make it more effective?
Some studies mainly comparing it to fluoxitine suggest potentially higher remission rates, but it's not universally accepted as superior to all SSRIs.
Any specific side effects to watch for with vinax vaccine?
The main one to be aware of is a potential dose related increase in blood pressure. It's not super common, but more likely at doses over 225 milligrams. So monitoring blood pressure, especially at higher doses, is generally recommended.
Okay. What about other SNRIs? Does Venlaxine?
That's the active metabolite of Venlaxine. It might have slightly fewer drug interactions because of metabolism differences. Efficacy is generally seen as similar and it has shown some use specifically in perry and post-menopausal women with depression.
Common side effects
things like insomnia, maybe drowsiness, dizziness, nausea are pretty common.
And deloxitine.
Delloxitine hits both serotonin and norepinephrine right from the starting dose, usually 60 milligrams daily. It also has indications for things like neuropathic pain and fibromyalgia.
Right. Useful if those conditions coexist.
Exactly. A key point for Delloxitine is its metabolism. It uses the CY P1 A2 enzyme.
Ah, so smoking could affect it.
Precisely.
Smoking induces CYP1 YA which can lower delloxitine levels. You might need dose adjustments in smokers.
Good clinical pearl. And Levlazoprin.
Levlasoprine is interesting because it has a higher selectivity for norepinephrine compared to serotonin reuptake. Common side effects include nausea, headache, dry mouth, sweating, constipation, dizziness.
Any cardiovascular effects?
Yes, it can potentially increase blood pressure and heart rate. So monitoring might be needed especially in patients with existing cardiovascular issues.
Okay, moving on to the dualaction anti-depressants category in our source. First up is bupropion. What's its deal?
Bupropion is quite different. It works mainly on norepinephrine and dopamine reuptake, not so much serotonin. It's a first-line agent for MDD and of course also used for smoking sessation.
What's the big warning with bupropion?
Seizure risk. It lowers the seizure threshold. And this effect is dose dependent. So it's contraindicated if someone has a seizure disorder or a history of anorexia or bulimia which also increase risk. Caution is needed with head trauma history too.
But on the plus side,
less GI upset and significantly less sexual dysfunction compared to SSRIs. That's a major advantage for some patients.
Okay. And the other one in this category,
mortazzipene.
Mertzipene works differently again. It enhances neurogeneric and serotonin activity but mainly through blocking certain receptors. Al adrenuric and some serotonin receptors.
What a effect profile.
Generally lower rates of GI and sexual side effects compared to SSRIs. However,
there's always a however.
Yeah, it's often associated with sedation especially at lower doses paradoxically and weight gain. Those can be significant drawbacks for some.
Right. Okay. Next category. Other serotonin modulators. Trazadone first. Often used for sleep. Right.
Exactly. It's a serotonin 2 receptor antagonist and weak reuptake inhibitor at anti-depressant doses. It's usually too sedating for daytime use for most people.
So lower doses at night.
Yes. Commonly used off label at lower doses, maybe 50, 100 milligrams as a sleep aid, often alongside another anti-depressant. An advantage is that tolerance to the sedative effect doesn't usually develop like it can with benzoazipines.
Okay. Vardioitine is next. We touched on its good balance earlier. What about its mechanism?
It's called multimodal. It inhibits the serotonin transporter like an SSRI, but also acts directly on several other serotonin receptors, antagonizing some, agonizing others.
Any unique benefits?
There's some interesting data suggesting it might improve cognitive function, like attention, processing speed in patients with MDD, which is a potential advantage.
Side effects,
mainly GI, nausea being the most common, but it often improves after the first week or so. Evidence suggests potentially lower rates of sexual dysfunction and sleep issues compared to typical SSRIs, but still needs monitoring.
And the last one here, Velozo. Plazadone combines SSRI activity with being a partial agonist at the 5HT1A receptor.
Anything special about taking it?
Yes, it needs to be taken with food for proper absorption. That's important counseling. And usually you start low and titrate up gradually to minimize GI side effects
which are
most common are nausea, diarrhea, headache. But like vioitine, it seems to have a lower frequency of sexual side effects compared to standard SSRIs.
Good to know. Okay, let's talk tricyclic antidepressants.
TCA case generally second line you said why
primarily because of tolerability and safety concerns they hit multiple receptors histamine acetylcholine alpha adinuric leading to more side effects like sedation dry mouth constipation dizziness and the big one is cardiotoxicity and overdose it can be lethal
the examples
amatipptalign nippalign desoperine clomoprein doxpin tremoprammin they vary a bit in their norepinephrine versus serotonin effects
Good clinical pearl. And Levlazoprin.
Levlasoprine is interesting because it has a higher selectivity for norepinephrine compared to serotonin reuptake. Common side effects include nausea, headache, dry mouth, sweating, constipation, dizziness.
Any cardiovascular effects?
Yes, it can potentially increase blood pressure and heart rate. So monitoring might be needed especially in patients with existing cardiovascular issues.
Okay, moving on to the dualaction anti-depressants category in our source. First up is bupropion. What's its deal?
Bupropion is quite different. It works mainly on norepinephrine and dopamine reuptake, not so much serotonin. It's a first-line agent for MDD and of course also used for smoking sessation.
What's the big warning with bupropion?
Seizure risk. It lowers the seizure threshold. And this effect is dose dependent. So it's contraindicated if someone has a seizure disorder or a history of anorexia or bulimia which also increase risk. Caution is needed with head trauma history too.
But on the plus side,
less GI upset and significantly less sexual dysfunction compared to SSRIs. That's a major advantage for some patients.
Okay. And the other one in this category,
mortazzipene.
Mertzipene works differently again. It enhances neurogeneric and serotonin activity but mainly through blocking certain receptors. Al adrenuric and some serotonin receptors.
What a effect profile.
Generally lower rates of GI and sexual side effects compared to SSRIs. However,
there's always a however.
Yeah, it's often associated with sedation especially at lower doses paradoxically and weight gain. Those can be significant drawbacks for some.
Right. Okay. Next category. Other serotonin modulators. Trazadone first. Often used for sleep. Right.
Exactly. It's a serotonin 2 receptor antagonist and weak reuptake inhibitor at anti-depressant doses. It's usually too sedating for daytime use for most people.
So lower doses at night.
Yes. Commonly used off label at lower doses, maybe 50, 100 milligrams as a sleep aid, often alongside another anti-depressant. An advantage is that tolerance to the sedative effect doesn't usually develop like it can with benzoazipines.
Okay. Vardioitine is next. We touched on its good balance earlier. What about its mechanism?
It's called multimodal. It inhibits the serotonin transporter like an SSRI, but also acts directly on several other serotonin receptors, antagonizing some, agonizing others.
Any unique benefits?
There's some interesting data suggesting it might improve cognitive function, like attention, processing speed in patients with MDD, which is a potential advantage.
Side effects,
mainly GI, nausea being the most common, but it often improves after the first week or so. Evidence suggests potentially lower rates of sexual dysfunction and sleep issues compared to typical SSRIs, but still needs monitoring.
And the last one here, Velozo. Plazadone combines SSRI activity with being a partial agonist at the 5HT1A receptor.
Anything special about taking it?
Yes, it needs to be taken with food for proper absorption. That's important counseling. And usually you start low and titrate up gradually to minimize GI side effects
which are
most common are nausea, diarrhea, headache. But like vioitine, it seems to have a lower frequency of sexual side effects compared to standard SSRIs.
Good to know. Okay, let's talk tricyclic antidepressants.
TCA case generally second line you said why
primarily because of tolerability and safety concerns they hit multiple receptors histamine acetylcholine alpha adinuric leading to more side effects like sedation dry mouth constipation dizziness and the big one is cardiotoxicity and overdose it can be lethal
the examples
amatipptalign nippalign desoperine clomoprein doxpin tremoprammin they vary a bit in their norepinephrine versus serotonin effects
any specific uses still Clomopramine is still often considered a good choice for OCD obsessivempulsive disorder due to its strong serotonin effects.
Right. And then monoamine oxidase inhibitors mais these sound serious.
They are the irreversible ones phenoline and tranylermen are generally third line used in specialized clinics.
Why the caution?
Big risk of interactions. The classic one is hypertensive crisis if combined with tyramine rich foods, aged cheeses, cured meats, certain beers. Also risk of serotonin syndrome with other serotoninergic drugs. Strict dietary and medication restrictions are vital.
So high-risisk profile
definitely. But there's also mlobamide.
How is that different?
It's a reversible and selective inhibitor of MAOA or RIMA. At standard doses, it generally doesn't need the strict dietary restrictions. It's better tolerated and can be a useful option sometimes, particularly if there's a lot of anxiety alongside the depression.
Okay. What about using atypical antiscychotics for depression?
Yeah, they're mainly used as augment ation meaning adding them on when an anti-depressant alone hasn't worked well enough.
Which ones?
Extended release quichipene is actually approved as monotherapy. Second line, the immediate release version is sometimes used but is more sedating. Then you have arapiprazole and brexiprazol approved specifically as add-ons to anti-depressants for inadequate response.
Any others used off label?
Alanzipene and respperadone are sometimes used off label as adjuncts too in treatment resistant situations.
How quickly should you see a response? If you add one,
generally if it's going to help, you should see some improvement within about 2 weeks.
Okay. And lastly, the NMDA receptor antagonist. This is newer territory, right?
Relatively, yes. Esetamine, the intraasal spray, is approved in Canada for treatment resistant depression, but only alongside an oral SSRI or SNRI.
Any restrictions?
Oh, yes. It's under a controlled distribution program because of potential dissociation, sedation, and misuse potential. Needs to be administered in a certified setting. and ketamine itself. For ketamine,
foreign ketamine has shown rapid anti-depressant effects in studies. Canmat considers it a thirdline option for treatment resistant depression based on short-term data. Again, usually administered in specialized clinics due to monitoring needs.
Wow. Okay, that covers the main classes. Let's circle back briefly to adverse effects in general. Key takeaways for the PDC.
Table four in the source is your friend here. It lists common side effects and management strategies. Big picture. If side effects are severe, persistent, or just not tolerable, you need to think about reducing the dose or switching meds.
Common ones to expect across classes,
GI upset, activation or anxiety initially, sleepiness or trouble sleeping, weight changes, gain is common with some, loss with others initially, and sexual dysfunction. Know which drugs are more prone to which effects.
And serotonin syndrome,
yes, be aware of it. Rare but serious. Caused by too much serotonin, usually from combining multiple serotonin drugs. Know the symptoms like confusion, agitation, rapid heart rate, sweating, tremor, rigidity, and that management involves stopping the offending agents and providing supportive care.
Okay. What about stopping anti-depressants? Discontinuation syndrome.
Very important counseling point. Stopping abruptly or reducing the dose too quickly can cause this. It's common, especially with SSRIs, just because they're used so much, but can happen with most anti-depressants taken for say 6 weeks or more.
Which drugs are highest risk?
Those with shorter half- livives. Peroxitine and venaxine are classic Examples, fluoxitine with its long halflife is the least likely. Symptoms
can be varied. Dizziness, nausea, lethargy, headache, anxiety, irritability, insomnia, sometimes weird sensory stuff like brain zaps
can feel like the flu.
So, how to manage it?
Tapering. Gradually reduce the dose.
Right. And then monoamine oxidase inhibitors mais these sound serious.
They are the irreversible ones phenoline and tranylermen are generally third line used in specialized clinics.
Why the caution?
Big risk of interactions. The classic one is hypertensive crisis if combined with tyramine rich foods, aged cheeses, cured meats, certain beers. Also risk of serotonin syndrome with other serotoninergic drugs. Strict dietary and medication restrictions are vital.
So high-risisk profile
definitely. But there's also mlobamide.
How is that different?
It's a reversible and selective inhibitor of MAOA or RIMA. At standard doses, it generally doesn't need the strict dietary restrictions. It's better tolerated and can be a useful option sometimes, particularly if there's a lot of anxiety alongside the depression.
Okay. What about using atypical antiscychotics for depression?
Yeah, they're mainly used as augment ation meaning adding them on when an anti-depressant alone hasn't worked well enough.
Which ones?
Extended release quichipene is actually approved as monotherapy. Second line, the immediate release version is sometimes used but is more sedating. Then you have arapiprazole and brexiprazol approved specifically as add-ons to anti-depressants for inadequate response.
Any others used off label?
Alanzipene and respperadone are sometimes used off label as adjuncts too in treatment resistant situations.
How quickly should you see a response? If you add one,
generally if it's going to help, you should see some improvement within about 2 weeks.
Okay. And lastly, the NMDA receptor antagonist. This is newer territory, right?
Relatively, yes. Esetamine, the intraasal spray, is approved in Canada for treatment resistant depression, but only alongside an oral SSRI or SNRI.
Any restrictions?
Oh, yes. It's under a controlled distribution program because of potential dissociation, sedation, and misuse potential. Needs to be administered in a certified setting. and ketamine itself. For ketamine,
foreign ketamine has shown rapid anti-depressant effects in studies. Canmat considers it a thirdline option for treatment resistant depression based on short-term data. Again, usually administered in specialized clinics due to monitoring needs.
Wow. Okay, that covers the main classes. Let's circle back briefly to adverse effects in general. Key takeaways for the PDC.
Table four in the source is your friend here. It lists common side effects and management strategies. Big picture. If side effects are severe, persistent, or just not tolerable, you need to think about reducing the dose or switching meds.
Common ones to expect across classes,
GI upset, activation or anxiety initially, sleepiness or trouble sleeping, weight changes, gain is common with some, loss with others initially, and sexual dysfunction. Know which drugs are more prone to which effects.
And serotonin syndrome,
yes, be aware of it. Rare but serious. Caused by too much serotonin, usually from combining multiple serotonin drugs. Know the symptoms like confusion, agitation, rapid heart rate, sweating, tremor, rigidity, and that management involves stopping the offending agents and providing supportive care.
Okay. What about stopping anti-depressants? Discontinuation syndrome.
Very important counseling point. Stopping abruptly or reducing the dose too quickly can cause this. It's common, especially with SSRIs, just because they're used so much, but can happen with most anti-depressants taken for say 6 weeks or more.
Which drugs are highest risk?
Those with shorter half- livives. Peroxitine and venaxine are classic Examples, fluoxitine with its long halflife is the least likely. Symptoms
can be varied. Dizziness, nausea, lethargy, headache, anxiety, irritability, insomnia, sometimes weird sensory stuff like brain zaps
can feel like the flu.
So, how to manage it?
Tapering. Gradually reduce the dose.
A common suggestion is maybe 25% reduction per week, but it needs to be individualized. Monitor for withdrawal symptoms and also for relapse of the depression itself.
Is it dangerous?
Generally, no. It's uncomfortable but not life-threatening. Usually resolves within say 3 weeks. Reassure patients about that. If symptoms are bad, you might need to restart the drug and taper much more slowly or sometimes use fluoxitine to help bridge the taper because of its long halflife.
Got it. Okay. Special populations, pregnancy, and breastfeeding. What are the key considerations?
It's always a risk benefit discussion. Weighing the risks of medication exposure against the risks of untreated maternal depression, which can also harm both mother and baby. So for pregnancy
psychotherapy is first line for mild moderate for moderate severe especially with prior history antid-depressants are often considered firstline treatment.
Which ones are preferred?
Often citellopram esopram and certuline are considered firstline due to having more reassuring safety data. Peroxitine has some concerns particularly regarding cardiac malf forations and fluoxitine's long halflife can be a consideration near delivery.
What to avoid?
Mis are generally avoided. Doc's been too
and postpartum especially with breastfeeding.
Postpartum blues are common and usually pass. For postpartum depression, psychotherapy again is a great first step. If meds are needed while breastfeeding, certuline alprag and citalopram are often preferred first-line choices because relatively low amounts get into breast milk.
Avoid docuin here too.
Yes, docin is generally not recommended during breastfeeding due to potential infant sedation. Always consult current guidelines for this area.
Absolutely. Now, the source has offered some great therapeuticips. tips. Can we highlight a few really key ones for PBC prep?
Definitely. One good tip, try to get really comfortable with maybe one or two agents from each major class. Know their dosing, side effects, interactions really well.
Makes sense. Avoid being overwhelmed.
Exactly. Always individualized treatment. Consider coorbidities. What symptoms are most bothersome for this patient?
And communicate well.
Crucial. Talk about side effects, interactions, discontinuation potential before they start. Provide that psycho education, what to expect, importance of adherence right at the beginning and reinforce it.
Combination therapy
often superior. Combining meds and psychotherapy like CBT or IP frequently gives better outcomes than either alone. Meds might work faster, but therapy can help reduce long-term relapse risk. Stress the importance of maintenance therapy.
What about things like drug level monitoring or genetic testing?
Generally, limited role in routine practice right now. Maybe in specific complex cases, but not standard first-line guidance. And if someone isn't responding,
review everything. Adherence, diagnosis correct, coorbidities addressed. After maybe two or three failed trials, or if psychosis or acute suicidality appears, definitely consider a psychiatric consult.
Then the taper again.
Yes, taper slowly when stopping. Especially peroxitine and venla vaccine. Think four or 6 weeks, maybe longer.
Great summary. And table six, the big drug table.
Invaluable resource. It has specifics on brand names, dosages, side effects. key interactions for pretty much all the anti-depressants we've discussed, plus antiscychotics used as adjuncts, MAOIs, even things like St. John's wart, your go-to for detailed drug info.
Speaking of which, natural health products. What's the quick takeaway?
St. John's wart has some evidence for mild moderate depression, but huge e potential for drug interactions. Check carefully. Sam has less robust evidence, generally well tolerated, but still carries a serotonin syndrome risk with other serotonergics.
Omega-3s, vitamin D, studied, but currently the evidence for benefit in depression is considered low quality, not primary treatments.
Is it dangerous?
Generally, no. It's uncomfortable but not life-threatening. Usually resolves within say 3 weeks. Reassure patients about that. If symptoms are bad, you might need to restart the drug and taper much more slowly or sometimes use fluoxitine to help bridge the taper because of its long halflife.
Got it. Okay. Special populations, pregnancy, and breastfeeding. What are the key considerations?
It's always a risk benefit discussion. Weighing the risks of medication exposure against the risks of untreated maternal depression, which can also harm both mother and baby. So for pregnancy
psychotherapy is first line for mild moderate for moderate severe especially with prior history antid-depressants are often considered firstline treatment.
Which ones are preferred?
Often citellopram esopram and certuline are considered firstline due to having more reassuring safety data. Peroxitine has some concerns particularly regarding cardiac malf forations and fluoxitine's long halflife can be a consideration near delivery.
What to avoid?
Mis are generally avoided. Doc's been too
and postpartum especially with breastfeeding.
Postpartum blues are common and usually pass. For postpartum depression, psychotherapy again is a great first step. If meds are needed while breastfeeding, certuline alprag and citalopram are often preferred first-line choices because relatively low amounts get into breast milk.
Avoid docuin here too.
Yes, docin is generally not recommended during breastfeeding due to potential infant sedation. Always consult current guidelines for this area.
Absolutely. Now, the source has offered some great therapeuticips. tips. Can we highlight a few really key ones for PBC prep?
Definitely. One good tip, try to get really comfortable with maybe one or two agents from each major class. Know their dosing, side effects, interactions really well.
Makes sense. Avoid being overwhelmed.
Exactly. Always individualized treatment. Consider coorbidities. What symptoms are most bothersome for this patient?
And communicate well.
Crucial. Talk about side effects, interactions, discontinuation potential before they start. Provide that psycho education, what to expect, importance of adherence right at the beginning and reinforce it.
Combination therapy
often superior. Combining meds and psychotherapy like CBT or IP frequently gives better outcomes than either alone. Meds might work faster, but therapy can help reduce long-term relapse risk. Stress the importance of maintenance therapy.
What about things like drug level monitoring or genetic testing?
Generally, limited role in routine practice right now. Maybe in specific complex cases, but not standard first-line guidance. And if someone isn't responding,
review everything. Adherence, diagnosis correct, coorbidities addressed. After maybe two or three failed trials, or if psychosis or acute suicidality appears, definitely consider a psychiatric consult.
Then the taper again.
Yes, taper slowly when stopping. Especially peroxitine and venla vaccine. Think four or 6 weeks, maybe longer.
Great summary. And table six, the big drug table.
Invaluable resource. It has specifics on brand names, dosages, side effects. key interactions for pretty much all the anti-depressants we've discussed, plus antiscychotics used as adjuncts, MAOIs, even things like St. John's wart, your go-to for detailed drug info.
Speaking of which, natural health products. What's the quick takeaway?
St. John's wart has some evidence for mild moderate depression, but huge e potential for drug interactions. Check carefully. Sam has less robust evidence, generally well tolerated, but still carries a serotonin syndrome risk with other serotonergics.
Omega-3s, vitamin D, studied, but currently the evidence for benefit in depression is considered low quality, not primary treatments.
Okay, so wrapping this up, this deep dive aimed to give you, our QBC candidate listeners, a concise but thorough overview of key antid-depressant info from the CTC reference, thanks to the Farmer Board Group.
Yeah, we've tried to pull out the essential choices, algorithm points, table highlights, and practical tips for your exam prep and understanding.
We really encourage you to go back to the source materials, though, especially table three on classifications. Table four on side effects, table six on specific drugs, and figure one the treatment algorithm.
Definitely dig into those for the full picture. They'll really solidify your understanding.
All right, time for a quick check. Here's a multiple choice question based on our discussion. Which of the following SSRI is least likely to be associated with discontinuation syndrome upon a bre sessation? Is it A peroxitine, bellaxine, C fluoxitine, or d certine? Think about halflife there. Pause. The answer is C. Fluoxitine due to its long half-life allowing for a sort of self taper.
Nicely explained.
And just as a final thought, remember this field is always evolving. New research, updated guidelines. Staying current is absolutely key for providing the best possible care to your patients in the future.
Absolutely. This deep dive brought to you by the Pharma Board Group using the CTC reference hopefully provided that clarity, accuracy, and practical insight you need for exam success and beyond. Thanks for joining us.
Yeah, we've tried to pull out the essential choices, algorithm points, table highlights, and practical tips for your exam prep and understanding.
We really encourage you to go back to the source materials, though, especially table three on classifications. Table four on side effects, table six on specific drugs, and figure one the treatment algorithm.
Definitely dig into those for the full picture. They'll really solidify your understanding.
All right, time for a quick check. Here's a multiple choice question based on our discussion. Which of the following SSRI is least likely to be associated with discontinuation syndrome upon a bre sessation? Is it A peroxitine, bellaxine, C fluoxitine, or d certine? Think about halflife there. Pause. The answer is C. Fluoxitine due to its long half-life allowing for a sort of self taper.
Nicely explained.
And just as a final thought, remember this field is always evolving. New research, updated guidelines. Staying current is absolutely key for providing the best possible care to your patients in the future.
Absolutely. This deep dive brought to you by the Pharma Board Group using the CTC reference hopefully provided that clarity, accuracy, and practical insight you need for exam success and beyond. Thanks for joining us.
اختلالات غذا خوردن
Welcome back to the deep dive.
So, uh, today we're tackling a really critical area, eating disorders.
We're aiming this squarely at you, the Canadian Pharmacist PBC candidates, focusing on what you absolutely need to know.
Exactly. We've gone through a pretty comprehensive chapter provided by the Pharma Board Group uh, based on that CTC reference. It's updated as of January 28, 2025 and peer reviewed back on October 1st, 2024 by Seard Birmingham.
Right. And our mission today basically to pull the key details, the definitions, therapeutic options, you know, meds, non-meds, the tables, those essential tips. We want to give you a clear, concise summary for your practice and of course for exam success.
Absolutely. Because as pharmacists, you know, you're a vital part of the team. Understanding these disorders, the nuances, the meds, potential issues, seeing red flags is just so important for patient care and working well with others.
Okay, let's jump right in. Then the chapter covers four main ones. Anorexia nervosa, bumia nervosa, binge eating disorder, and ARFID that's avoidant restrictive food intake disorder. Let's start with anorexia nervosa. So the core is that distorted body image, really intense dieting, severe weight loss, and this uh overpowering fear of gaining weight. What's a really key distinction within anorexia we should like keep in mind?
Well, what's really important to grasp is that it's not just one thing. You've got the restricting type where people severely limit food and then the binge eating, purging type. And crucially, patients might actually move between these types. They don't always stay in one box.
Oh, okay. So, they can switch.
Yeah. Or alternate.
And while we often think of it affecting younger females, the chapter rightly points out males are affected too. And importantly, it uses female and male, but acknowledges that might not fit everyone's identity, which underlines, you know, the need for individual care.
That's a really good point about the fluidity between types. Now, table one in the chapter gives the DSM5TR criteria for anorexia. Criterion A is that energy restriction leading to significantly low body weight. It gives BMI categories for adults. Mild is 17 plus, moderate 16, 1699, severe 151599, and extreme under 15.
Right? Then you have criterion B that intense fear of weight gain, and C the disturbance in how they see their body weight or shape. The table also mentions partial and full remission useful for tracking recovery.
So, what are the big goals when treating anorexia? It's not just about the number on the scale, right?
Not at all. It's about normalizing body fat, weight, growth, maybe getting frustration back if applicable, but also reducing that fear of weight gain, improving strength, cognitive function, reducing or stopping binge purge behaviors, encouraging healthy eating, and ultimately preventing relapse. It's uh quite comprehensive.
Okay. So, if you suspect anorexia, what kind of initial workup should happen?
This is where a really thorough assessment is key. The chapter stresses a detailed history, weight history, eating patterns, periods, body image stuff, any compensatory beh behaviors like vomiting or laxatives. Also screening for depression, anxiety, suicidal thoughts,
family issues, abuse history, malnutrition symptoms, any autonomic issues like dizziness, fainting, plus developmental and psychological history, diet history, including what they avoid and why.
And the physical exam,
yeah, that might show things like swollen parotted glands, maybe edema, dental problems, Russell sign on the knuckles, postural hypotension, fast heart rate, maybe that fine lenugo hair, yellowish skin from hypercarmia, checking weight height changes, body fat, muscle weakness, signs of low calcium like chiovastcs or truso signs.
Wow, lots to look for and labs. Table two seems helpful there.
Definitely. Table two breaks down the recommended lab tests.
Welcome back to the deep dive.
So, uh, today we're tackling a really critical area, eating disorders.
We're aiming this squarely at you, the Canadian Pharmacist PBC candidates, focusing on what you absolutely need to know.
Exactly. We've gone through a pretty comprehensive chapter provided by the Pharma Board Group uh, based on that CTC reference. It's updated as of January 28, 2025 and peer reviewed back on October 1st, 2024 by Seard Birmingham.
Right. And our mission today basically to pull the key details, the definitions, therapeutic options, you know, meds, non-meds, the tables, those essential tips. We want to give you a clear, concise summary for your practice and of course for exam success.
Absolutely. Because as pharmacists, you know, you're a vital part of the team. Understanding these disorders, the nuances, the meds, potential issues, seeing red flags is just so important for patient care and working well with others.
Okay, let's jump right in. Then the chapter covers four main ones. Anorexia nervosa, bumia nervosa, binge eating disorder, and ARFID that's avoidant restrictive food intake disorder. Let's start with anorexia nervosa. So the core is that distorted body image, really intense dieting, severe weight loss, and this uh overpowering fear of gaining weight. What's a really key distinction within anorexia we should like keep in mind?
Well, what's really important to grasp is that it's not just one thing. You've got the restricting type where people severely limit food and then the binge eating, purging type. And crucially, patients might actually move between these types. They don't always stay in one box.
Oh, okay. So, they can switch.
Yeah. Or alternate.
And while we often think of it affecting younger females, the chapter rightly points out males are affected too. And importantly, it uses female and male, but acknowledges that might not fit everyone's identity, which underlines, you know, the need for individual care.
That's a really good point about the fluidity between types. Now, table one in the chapter gives the DSM5TR criteria for anorexia. Criterion A is that energy restriction leading to significantly low body weight. It gives BMI categories for adults. Mild is 17 plus, moderate 16, 1699, severe 151599, and extreme under 15.
Right? Then you have criterion B that intense fear of weight gain, and C the disturbance in how they see their body weight or shape. The table also mentions partial and full remission useful for tracking recovery.
So, what are the big goals when treating anorexia? It's not just about the number on the scale, right?
Not at all. It's about normalizing body fat, weight, growth, maybe getting frustration back if applicable, but also reducing that fear of weight gain, improving strength, cognitive function, reducing or stopping binge purge behaviors, encouraging healthy eating, and ultimately preventing relapse. It's uh quite comprehensive.
Okay. So, if you suspect anorexia, what kind of initial workup should happen?
This is where a really thorough assessment is key. The chapter stresses a detailed history, weight history, eating patterns, periods, body image stuff, any compensatory beh behaviors like vomiting or laxatives. Also screening for depression, anxiety, suicidal thoughts,
family issues, abuse history, malnutrition symptoms, any autonomic issues like dizziness, fainting, plus developmental and psychological history, diet history, including what they avoid and why.
And the physical exam,
yeah, that might show things like swollen parotted glands, maybe edema, dental problems, Russell sign on the knuckles, postural hypotension, fast heart rate, maybe that fine lenugo hair, yellowish skin from hypercarmia, checking weight height changes, body fat, muscle weakness, signs of low calcium like chiovastcs or truso signs.
Wow, lots to look for and labs. Table two seems helpful there.
Definitely. Table two breaks down the recommended lab tests.
It flags tests related to restriction electrolytes, creatinine, B12, feritin, ECG, blood counts, and also those often linked to purging. Again, electrolytes your analysis. There's overlap, of course.
And the chapter points out that abnormal electrolytes are linked to worse outcomes. That seems critical.
It is. is and it also reminds us that BMI isn't everything which is so important for a holistic view
right so if weight doesn't start picking up in say a month or two
then the recommendation is a deeper dive with a psychiatric and nutritional assessment
okay let's talk treatment non-farmacologic first what are the cornerstones there
well first off building that rapport that trust that's fundamental then psychotherapy is huge CBT family therapy interpersonal therapy are mentioned for kids and teens means family involvement is really emphasized. They even mentioned the Modsley method which empowers parents,
right? Getting the family on board.
Yeah. And nutritional support is obviously critical. Step-wise goals with a dietitian, maybe supplements like insure or boost, supervised meals, sometimes even tube feeding if necessary
and exercise.
Initially, limiting exercise is usually advised, maybe with gradual supervised reintroduction later. Plus, simple things like warming strategies can help manage anxiety and setting goals around stopping binge purge. behaviors, too.
That's interesting about needing some weight restoration for therapy to really stick.
Yeah, it highlights that mindbody connection. Psychological treatment often works better once the brain has enough nourishment basically.
Okay, let's look at the meds. Table three. It sounds like these are mostly for specific symptoms or other conditions.
Exactly. They aren't typically curing the anorexia itself, but managing complications like gastroparesis that slowed stomach emptying.
Right. Dumperidone is preferred over medical Operide
generally yes fewer movement side effects but there's a heads up about potential QTC prolongation the heart rhythm thing so ECG monitoring is suggested especially with dumperadone
and if those don't work
ariththramycin or isithramycin might be tried but effectiveness can fade for constipation procalopride gets a mention and importantly it doesn't seem to have those cardiac issues
what else is in the toolbox pharmacologically
zinc gluconate might help with weight gain sometimes even if levels look Normal nausea can be a side effect though. Lowdos alanzipene and antiscychotic might be used for really rigid delusional thinking or obsessive thoughts about food and weight
but not for rapid weight gain.
No, the weight gain is usually modest and it's typically shortterm because of risks like movement disorders and metabolic problems down the line.
Okay.
Cypereptadine, an older antihistamine, might give a bit of weight gain and can help with sleep if taken at bedtime
and anxiety. Benzo seemed like a bad idea. idea here.
Yeah, the chapter strongly advises against benzoazipines, lack of evidence for anxiety and anorexia, plus misuse potential. Quesipine, another antiscychotic, is maybe an alternative for anxiety, but again, side effects to consider.
And SSRIs
generally only if there's a definite coexisting depression or anxiety and crucially only once the patient is medically stable, especially cardiac wise.
Got it. And thamine.
Oh, absolutely. Vital. Give thamine right at the start of refeeding to prevent vernick cors syndrome. That's non-negotiable.
Some really key therapeutic tips here, too. Risk of hypoglycemia when starting to eat again.
Yes, low blood sugar. Need to watch for that. And managing chronic laxative abuse needs careful tapering. Maybe using pukalopride
and refeeding syndrome. That sounds serious.
It is very serious. Those electrolyte shifts, especially low phosphate, needs experienced clinicians. It can be life-threatening.
Good to know. The chapter also reminds us pregnancy can happen even without periods. Treatment refusal is common,
And the chapter points out that abnormal electrolytes are linked to worse outcomes. That seems critical.
It is. is and it also reminds us that BMI isn't everything which is so important for a holistic view
right so if weight doesn't start picking up in say a month or two
then the recommendation is a deeper dive with a psychiatric and nutritional assessment
okay let's talk treatment non-farmacologic first what are the cornerstones there
well first off building that rapport that trust that's fundamental then psychotherapy is huge CBT family therapy interpersonal therapy are mentioned for kids and teens means family involvement is really emphasized. They even mentioned the Modsley method which empowers parents,
right? Getting the family on board.
Yeah. And nutritional support is obviously critical. Step-wise goals with a dietitian, maybe supplements like insure or boost, supervised meals, sometimes even tube feeding if necessary
and exercise.
Initially, limiting exercise is usually advised, maybe with gradual supervised reintroduction later. Plus, simple things like warming strategies can help manage anxiety and setting goals around stopping binge purge. behaviors, too.
That's interesting about needing some weight restoration for therapy to really stick.
Yeah, it highlights that mindbody connection. Psychological treatment often works better once the brain has enough nourishment basically.
Okay, let's look at the meds. Table three. It sounds like these are mostly for specific symptoms or other conditions.
Exactly. They aren't typically curing the anorexia itself, but managing complications like gastroparesis that slowed stomach emptying.
Right. Dumperidone is preferred over medical Operide
generally yes fewer movement side effects but there's a heads up about potential QTC prolongation the heart rhythm thing so ECG monitoring is suggested especially with dumperadone
and if those don't work
ariththramycin or isithramycin might be tried but effectiveness can fade for constipation procalopride gets a mention and importantly it doesn't seem to have those cardiac issues
what else is in the toolbox pharmacologically
zinc gluconate might help with weight gain sometimes even if levels look Normal nausea can be a side effect though. Lowdos alanzipene and antiscychotic might be used for really rigid delusional thinking or obsessive thoughts about food and weight
but not for rapid weight gain.
No, the weight gain is usually modest and it's typically shortterm because of risks like movement disorders and metabolic problems down the line.
Okay.
Cypereptadine, an older antihistamine, might give a bit of weight gain and can help with sleep if taken at bedtime
and anxiety. Benzo seemed like a bad idea. idea here.
Yeah, the chapter strongly advises against benzoazipines, lack of evidence for anxiety and anorexia, plus misuse potential. Quesipine, another antiscychotic, is maybe an alternative for anxiety, but again, side effects to consider.
And SSRIs
generally only if there's a definite coexisting depression or anxiety and crucially only once the patient is medically stable, especially cardiac wise.
Got it. And thamine.
Oh, absolutely. Vital. Give thamine right at the start of refeeding to prevent vernick cors syndrome. That's non-negotiable.
Some really key therapeutic tips here, too. Risk of hypoglycemia when starting to eat again.
Yes, low blood sugar. Need to watch for that. And managing chronic laxative abuse needs careful tapering. Maybe using pukalopride
and refeeding syndrome. That sounds serious.
It is very serious. Those electrolyte shifts, especially low phosphate, needs experienced clinicians. It can be life-threatening.
Good to know. The chapter also reminds us pregnancy can happen even without periods. Treatment refusal is common,
right? Which means needing to reassess the plan, maybe more family therapy for younger ones and clear indicators for specialist referral suicidality, worsening depression, just not gaining weight.
And the big message is early treatment is better.
Yeah. Different levels of care might be needed.
Exactly. Outpatient, day programs, inpatient depends on the severity.
Okay, let's switch gears. Bulimia and nervosa. How is this different?
So bulimia involves recurrent binge eating episodes followed by in appropriate compensatory behaviors, things like vomiting, laxative misuse, excessive exercise to prevent weight gain. A key difference from anorexia is that people with bulimia are usually in a normal weight range or sometimes overweight.
Okay? And the criteria in table one reflect that.
They do. Criterion A is the recurrent binges, large amount of food, feeling out of control. Criterion B is those recurrent inappropriate compensatory behaviors.
And C says both have to happen at least once a week for 3 months.
Correct. Criterion D is that self Fourth is overly tied to body shape and weight and e make sure it's not just happening during anorexia.
And severity is based on how often the compensatory behaviors happen.
Yes, mild, moderate, severe, extreme based on frequency per week.
What are the main goals for treating bulimia?
It's really about tackling the underlying thoughts and feelings driving that binge compensate cycle, helping establish normal eating, and of course treating any co-occurring issues like depression or suicidality.
Non-farmacologic approaches.
Yeah. CBT. Again,
CBT is definitely first line along with interpersonal therapy. Psychoeducational groups can also be beneficial and self-help approaches, books, online CBT, sometimes with support can play a role too.
And pharmacologically, table four. Antid-depressants seem key here.
Yes, anti-depressants are effective in reducing binge frequency. SSRIs, benlaxine, tisodone are options. Fluoxitine actually has the strongest evidence base.
Does it matter if they also have depression? Interestingly, no. The antibbolyic effect seems independent of whether they have diagnosed depression and no one anti-depressant is clearly better than others apart from fluoxitine having the most data. Trizone might be useful if insomnia is also a problem.
And the big warning,
bupropion absolutely contraindicated due to increased seizure risk in this population. Huge red flag.
Got it. How long should treatment continue?
If an anti-depressant works, continue for at least 6 months, ideally a year before considering a slow taper.
And TCA's MAOIS are are generally avoided.
Yeah. Due to toxicity risks and overdose and adherence challenges,
therapeutic tips for bulimia, anything specific jump out?
Well, the purging can mess with drug absorption, so timing of doses might need consideration.
Ah, practical point.
Also, symptoms might temporarily worsen during stress or even during therapy doesn't necessarily mean treatment isn't working overall. Avoid polyfarm pharmacy with anti-depressants if possible. Response varies, so sometimes you need to try a different agent and taper slowly when and stopping. Always treat coorbidities. A team approach is often best.
Okay, moving on to binge eating disorder or beed.
All right, so be involves recurrent binge eating with that sense of losing control. There's often relief during the binge, but then anxiety or guild after. The key distinction from bulimia is no regular compensatory behaviors.
Okay. And who gets this?
It affects all genders, often starts a bit later, maybe in the 30s, can be chronic and people often hide it due to shame. It can contrib ute to obesity or make it worse. There might be links to addiction, family history, stress, time of day, maybe even menstrual cycles.
The criterion table one again, criterion A is the recurrent binges, large amount, lack of control.
Yep. And criterion B needs at least three associated features.
And the big message is early treatment is better.
Yeah. Different levels of care might be needed.
Exactly. Outpatient, day programs, inpatient depends on the severity.
Okay, let's switch gears. Bulimia and nervosa. How is this different?
So bulimia involves recurrent binge eating episodes followed by in appropriate compensatory behaviors, things like vomiting, laxative misuse, excessive exercise to prevent weight gain. A key difference from anorexia is that people with bulimia are usually in a normal weight range or sometimes overweight.
Okay? And the criteria in table one reflect that.
They do. Criterion A is the recurrent binges, large amount of food, feeling out of control. Criterion B is those recurrent inappropriate compensatory behaviors.
And C says both have to happen at least once a week for 3 months.
Correct. Criterion D is that self Fourth is overly tied to body shape and weight and e make sure it's not just happening during anorexia.
And severity is based on how often the compensatory behaviors happen.
Yes, mild, moderate, severe, extreme based on frequency per week.
What are the main goals for treating bulimia?
It's really about tackling the underlying thoughts and feelings driving that binge compensate cycle, helping establish normal eating, and of course treating any co-occurring issues like depression or suicidality.
Non-farmacologic approaches.
Yeah. CBT. Again,
CBT is definitely first line along with interpersonal therapy. Psychoeducational groups can also be beneficial and self-help approaches, books, online CBT, sometimes with support can play a role too.
And pharmacologically, table four. Antid-depressants seem key here.
Yes, anti-depressants are effective in reducing binge frequency. SSRIs, benlaxine, tisodone are options. Fluoxitine actually has the strongest evidence base.
Does it matter if they also have depression? Interestingly, no. The antibbolyic effect seems independent of whether they have diagnosed depression and no one anti-depressant is clearly better than others apart from fluoxitine having the most data. Trizone might be useful if insomnia is also a problem.
And the big warning,
bupropion absolutely contraindicated due to increased seizure risk in this population. Huge red flag.
Got it. How long should treatment continue?
If an anti-depressant works, continue for at least 6 months, ideally a year before considering a slow taper.
And TCA's MAOIS are are generally avoided.
Yeah. Due to toxicity risks and overdose and adherence challenges,
therapeutic tips for bulimia, anything specific jump out?
Well, the purging can mess with drug absorption, so timing of doses might need consideration.
Ah, practical point.
Also, symptoms might temporarily worsen during stress or even during therapy doesn't necessarily mean treatment isn't working overall. Avoid polyfarm pharmacy with anti-depressants if possible. Response varies, so sometimes you need to try a different agent and taper slowly when and stopping. Always treat coorbidities. A team approach is often best.
Okay, moving on to binge eating disorder or beed.
All right, so be involves recurrent binge eating with that sense of losing control. There's often relief during the binge, but then anxiety or guild after. The key distinction from bulimia is no regular compensatory behaviors.
Okay. And who gets this?
It affects all genders, often starts a bit later, maybe in the 30s, can be chronic and people often hide it due to shame. It can contrib ute to obesity or make it worse. There might be links to addiction, family history, stress, time of day, maybe even menstrual cycles.
The criterion table one again, criterion A is the recurrent binges, large amount, lack of control.
Yep. And criterion B needs at least three associated features.
Eating super fast, eating till I'm comfortably full, eating lots when not hungry, eating alone due to embarrassment, feeling disgusted, depressed, guilty afterwards.
C is marked distress. D is frequency at least weekly for 3 months. months and E confirms no regular compensatory behaviors and it's not just doing anorexia or bulimia
and severity is based on binge frequency just like bulimia's compensatory behaviors
non-farmacologic treatment for beed what's the focus
identifying and managing triggers is big recommending structured eating like three meals a day with protein can help limiting large amounts of simple sugars the focus isn't usually strict dieting which can backfire but reducing binge likelihood and size CBT might also be tried self-help resources exist too and pharmacologic options. Table five, SSRIs. Again,
yes, SSRIs can help increase binge abstinence, reduce frequency, and help with the obsessive thoughts around it. Fluoxidine is mentioned as well tolerated. But interestingly, lizexetamine, which is an amphetamine based stimulant, is actually Health Canada approved for moderate to severe beed in adults.
Oh, really? A stimulant?
Yes. It's shown to reduce binge frequency, obsessions, compulsions, and it also tends to reduce appetite and weight. Seems generally well tolerated with careful dose titration.
What about topamate?
It's an anti-convulsant. It might reduce binge frequency and weight, but it has a pretty high rate of side effects, cognitive issues, depression, and people often stop taking it. So, not usually a first choice.
Key tips for managing beed.
Rule out other causes for the binging first. Diagnose and treat any family issues or other mental health conditions. Setting clear goals with the patient is vital. What exactly is a binge for them? What else matters besides just stopping the binges
and finding out what they've tried, what they want to try, what's acceptable to them.
Makes sense.
Okay, last one. Avoidant restrictive food intake disorder. A arfid,
right? Arfid is about avoiding or restricting food intake, but not because of body image concerns. It's usually based on sensory aspects, texture, taste, smell, or maybe a bad past experience with eating, like choking. It becomes ARFID if this avoidance compromises their health. or emotional or social well-being.
So the motivation is totally different from anorexia. The criteria in table one,
criterion A is that eating feeding disturbance leading to at least one major consequence, significant weight loss or growth failure, major nutritional deficiency, dependence on tube feeding or supplements, or marked interference with psychosocial functioning.
Okay.
B confirms it's not just lack of food or cultural practice. C states it's not during anorexia blemia and there's no body image disturbance. And D says it's not better explained by another medical or mental health issue unless it's way more severe than usual for that condition.
Therapy goals for ARFID.
Correcting nutritional deficiencies is primary. Addressing the related emotional and social issues, helping them become less sensitive or fearful of avoided foods, ensuring a healthy overall diet, allowing them to eat socially without extreme stress, and preventing relapse.
Non-farmacologic strategies seem central here.
Absolutely. Assess and treat their overall health, emotional state, social functioning correct deficiencies. The chapter mentions iron, zinc, B12, folate, vitamin C as potentially important for appetite, mood, taste. They even suggest trying zinc if the diet's low, even if blood levels look okay. Treat any co-occurring psych issues or stressors
and therapy techniques.
CBT is used decreasing avoidance, increasing exposure, targeting specific fears like vomiting or choking. It involves goal setting, education, self-monitoring, graded exposure, trying tiny bits of feared foods, and Anxiety management. Desensitization is key. Start with the least bothersome foods. Gradually work on texture, taste, smell issues, often in a relaxed setting, maybe with distractions.
C is marked distress. D is frequency at least weekly for 3 months. months and E confirms no regular compensatory behaviors and it's not just doing anorexia or bulimia
and severity is based on binge frequency just like bulimia's compensatory behaviors
non-farmacologic treatment for beed what's the focus
identifying and managing triggers is big recommending structured eating like three meals a day with protein can help limiting large amounts of simple sugars the focus isn't usually strict dieting which can backfire but reducing binge likelihood and size CBT might also be tried self-help resources exist too and pharmacologic options. Table five, SSRIs. Again,
yes, SSRIs can help increase binge abstinence, reduce frequency, and help with the obsessive thoughts around it. Fluoxidine is mentioned as well tolerated. But interestingly, lizexetamine, which is an amphetamine based stimulant, is actually Health Canada approved for moderate to severe beed in adults.
Oh, really? A stimulant?
Yes. It's shown to reduce binge frequency, obsessions, compulsions, and it also tends to reduce appetite and weight. Seems generally well tolerated with careful dose titration.
What about topamate?
It's an anti-convulsant. It might reduce binge frequency and weight, but it has a pretty high rate of side effects, cognitive issues, depression, and people often stop taking it. So, not usually a first choice.
Key tips for managing beed.
Rule out other causes for the binging first. Diagnose and treat any family issues or other mental health conditions. Setting clear goals with the patient is vital. What exactly is a binge for them? What else matters besides just stopping the binges
and finding out what they've tried, what they want to try, what's acceptable to them.
Makes sense.
Okay, last one. Avoidant restrictive food intake disorder. A arfid,
right? Arfid is about avoiding or restricting food intake, but not because of body image concerns. It's usually based on sensory aspects, texture, taste, smell, or maybe a bad past experience with eating, like choking. It becomes ARFID if this avoidance compromises their health. or emotional or social well-being.
So the motivation is totally different from anorexia. The criteria in table one,
criterion A is that eating feeding disturbance leading to at least one major consequence, significant weight loss or growth failure, major nutritional deficiency, dependence on tube feeding or supplements, or marked interference with psychosocial functioning.
Okay.
B confirms it's not just lack of food or cultural practice. C states it's not during anorexia blemia and there's no body image disturbance. And D says it's not better explained by another medical or mental health issue unless it's way more severe than usual for that condition.
Therapy goals for ARFID.
Correcting nutritional deficiencies is primary. Addressing the related emotional and social issues, helping them become less sensitive or fearful of avoided foods, ensuring a healthy overall diet, allowing them to eat socially without extreme stress, and preventing relapse.
Non-farmacologic strategies seem central here.
Absolutely. Assess and treat their overall health, emotional state, social functioning correct deficiencies. The chapter mentions iron, zinc, B12, folate, vitamin C as potentially important for appetite, mood, taste. They even suggest trying zinc if the diet's low, even if blood levels look okay. Treat any co-occurring psych issues or stressors
and therapy techniques.
CBT is used decreasing avoidance, increasing exposure, targeting specific fears like vomiting or choking. It involves goal setting, education, self-monitoring, graded exposure, trying tiny bits of feared foods, and Anxiety management. Desensitization is key. Start with the least bothersome foods. Gradually work on texture, taste, smell issues, often in a relaxed setting, maybe with distractions.
Any medications specifically for ARFD?
Not really for the ARFID itself, but medications might be used for co-occurring conditions like OCD, anxiety, or depression, which can sometimes go along with it. And it's noted as being more common in kids with autism spectrum disorder.
Therapeutic tips for ARFID.
Start desensitization with the easiest foods first. The goal isn't necessarily to eat everything, but to get to normalized nutrition and reduce the stress and lifestyle impact. If someone's underweight, initially focus on getting enough volume of their preferred foods. Exercise restriction might be needed initially if they're very malnourished. Supplements or tube feeding might be temporary bridges. And like with severe anorexia, watch for hypoglycemia and refeeding syndrome if malnutrition is severe.
Okay, one last important section. Pregnancy and breastfeeding.
Yes, really crucial for pharmacists. Point one. One, women with anorexia who aren't menrating can still ovulate and get pregnant.
Wow. Okay, good to know.
Pregnancy can sometimes improve symptoms, sometimes worsen them. There's a higher risk of some complications. Preeacclampsia, miscarriage, pre-term birth, C-section, small or large babies, perinatal death, also higher anxiety, depression,
but most deliveries are normal.
Yes, reassuringly, most have normal deliveries and healthy babies. A sadder point is that children of parents with eating disorders might end up in caregiver roles and have their own increased risk later.
Management during pregnancy.
Assess mental health carefully. Reassess all meds for pregnancy risk. Non-farmacologic is often preferred if possible. Monitor blood work closely. High-risisk OB followup if the ED is severe. Dietitian support is key.
And breastfeeding.
Severe anorexia might affect milk supply, but most can breastfeed. Again, dietitian support is vital for optimizing nutrition for both. And always consult specialized resources for medication safety in pregnancy. and lactation.
Great. So, let's try to bring it all together. Key takeaways for PVC candidates.
Okay. Bottom line. First, be able to recognize the different disorders based on those diagnostic criteria in table one anorexia, bulimia, beed, arad. Know the core features of each.
Right?
Second, understand the main treatment principles both non-farmacologic like CBT, nutritional rehab, family therapy, and pharmarmacologic referencing tables three, four, and five for specific meds uses. and important cautions
like the QTC risk with dumperadone or the bipopropian contraindication and bulimia.
Exactly. Third, be aware of major complications. Refeeding syndrome is a big one, hypoglycemia, effects of purging on drug absorption.
And finally, remember those special considerations during pregnancy and breastfeeding, reassessing meds, monitoring, team approach.
This info again from Pharma Board Group based on CTC reference should give you a really solid overview for the exam.
Absolutely. Okay, let's test that understanding. Here's a multiple choice this question for you listening. Which of the following is a recommended first-line pharmacologic treatment for bulimia nervosa according to the information discussed? Is it A bupropion, B fluoxitine, C to priorate or D alanzipine?
Think about the evidence strength we talked about and any major contraindications mentioned.
We definitely encourage you to go back and review the full chapter and any other resources you have for a deeper understanding. And please, we'd love to hear your feedback or any suggestions for future deep dive. is relevant to your practice or studies. Thanks so much for joining us for this deep dive.
Not really for the ARFID itself, but medications might be used for co-occurring conditions like OCD, anxiety, or depression, which can sometimes go along with it. And it's noted as being more common in kids with autism spectrum disorder.
Therapeutic tips for ARFID.
Start desensitization with the easiest foods first. The goal isn't necessarily to eat everything, but to get to normalized nutrition and reduce the stress and lifestyle impact. If someone's underweight, initially focus on getting enough volume of their preferred foods. Exercise restriction might be needed initially if they're very malnourished. Supplements or tube feeding might be temporary bridges. And like with severe anorexia, watch for hypoglycemia and refeeding syndrome if malnutrition is severe.
Okay, one last important section. Pregnancy and breastfeeding.
Yes, really crucial for pharmacists. Point one. One, women with anorexia who aren't menrating can still ovulate and get pregnant.
Wow. Okay, good to know.
Pregnancy can sometimes improve symptoms, sometimes worsen them. There's a higher risk of some complications. Preeacclampsia, miscarriage, pre-term birth, C-section, small or large babies, perinatal death, also higher anxiety, depression,
but most deliveries are normal.
Yes, reassuringly, most have normal deliveries and healthy babies. A sadder point is that children of parents with eating disorders might end up in caregiver roles and have their own increased risk later.
Management during pregnancy.
Assess mental health carefully. Reassess all meds for pregnancy risk. Non-farmacologic is often preferred if possible. Monitor blood work closely. High-risisk OB followup if the ED is severe. Dietitian support is key.
And breastfeeding.
Severe anorexia might affect milk supply, but most can breastfeed. Again, dietitian support is vital for optimizing nutrition for both. And always consult specialized resources for medication safety in pregnancy. and lactation.
Great. So, let's try to bring it all together. Key takeaways for PVC candidates.
Okay. Bottom line. First, be able to recognize the different disorders based on those diagnostic criteria in table one anorexia, bulimia, beed, arad. Know the core features of each.
Right?
Second, understand the main treatment principles both non-farmacologic like CBT, nutritional rehab, family therapy, and pharmarmacologic referencing tables three, four, and five for specific meds uses. and important cautions
like the QTC risk with dumperadone or the bipopropian contraindication and bulimia.
Exactly. Third, be aware of major complications. Refeeding syndrome is a big one, hypoglycemia, effects of purging on drug absorption.
And finally, remember those special considerations during pregnancy and breastfeeding, reassessing meds, monitoring, team approach.
This info again from Pharma Board Group based on CTC reference should give you a really solid overview for the exam.
Absolutely. Okay, let's test that understanding. Here's a multiple choice this question for you listening. Which of the following is a recommended first-line pharmacologic treatment for bulimia nervosa according to the information discussed? Is it A bupropion, B fluoxitine, C to priorate or D alanzipine?
Think about the evidence strength we talked about and any major contraindications mentioned.
We definitely encourage you to go back and review the full chapter and any other resources you have for a deeper understanding. And please, we'd love to hear your feedback or any suggestions for future deep dive. is relevant to your practice or studies. Thanks so much for joining us for this deep dive.
اختلالات اضطرابی
Welcome to the deep dive. If you're gearing up for the Canadian pharmacy PBC exam, you uh you definitely know how much material there is to cover.
It's a lot.
Yeah, a mountain. So, today we're tackling a big one. Anxiety disorders,
a very common and important topic.
Exactly. And we've really tried to distill a key resource for you. Uh this deep dive is brought to you by Pharma Board Group and it's based on the CTC reference.
Right. We've pulled out the essential therapeutic choices, medication algorithms, those key tables, and you know, practical tips you really need for the exam and for practice.
Think of it as maybe a focused review, helping you feel confident you've got the critical stuff covered in this area.
That's the goal, a concise, clear summary. We know that feeling prepared brings peace of mind, and that's what we want to help with.
And it's so relevant for Canadian pharmacists, isn't it? The numbers are pretty staggering.
They really are. Lifetime prevalence estimates are about what, 31% and maybe 24% of Canadians saying they've actually experienced an anxiety disord. order.
Wow. So, you will see this in practice frequently.
Absolutely. And what's also concerning is that they're often underdiagnosed, undertreated even,
which means there's a real role for pharmacists here.
A huge opportunity. Yeah. To help with recognition, support, guiding patients.
So, it's more than just exam prep. It's about good patient care down the line. Okay. So, what's the roadmap for this deep dive? What are we covering?
Well, we'll start with the basics definitions, DSM5TR classifications, then uh goals of therapy. What investigations might look like. Okay. The main part will be the treatments, non-farmacological and pharmacological options.
We'll also get into special populations, pregnancy, breastfeeding, kids, adolescence,
crucial areas.
Definitely. And we'll wrap up with some practical therapeutic tips you can actually use.
Sounds like a solid plan.
Yeah.
Let's jump right into therapeutic choices then. Uh starting with the non-farmacological side. What about psychoeducation? How important is that?
Oh, it's foundational really empower. ing patients with knowledge about their condition, what it is, treatment options, what makes it worse, how to spot early warning signs,
so they understand what's happening.
Exactly. And pharmacists can point them to great resources like uh Relief or Anxiety Canada, good websites, good info to supplement what you provide.
Makes sense. An informed patient is usually a more engaged patient.
Totally. More likely to stick with the plan, feel more in control.
Okay. What about actual therapies? We hear about C CBT exposure therapy.
Yeah, psychotherapy is a cornerstone for the PBC. The big ones to know are cognitive behavioral therapy, CBT exposure therapy, and mindfulness-based approaches. They've all got strong evidence.
CBT seems to come up a lot.
It does. It helps patients identify and change those unhelpful thought patterns and behaviors. Often considered firstline psychotherapy for many anxiety disorders.
What if someone can't easily get to facetoface therapy? Are there alternatives?
Yes, and this is increasingly important. delivered CBT or ICBT.
ICBT. Yeah.
Yeah. There was a big Cochran review showing it's definitely better than being on a weight list. And interestingly, when it includes the support, it seems pretty comparable to traditional face-to-face CBT for a lot of people.
That's really good to know, especially for accessibility.
Huge benefit for access. Yeah.
What else? Beyond formal therapy, lifestyle things.
Definitely. Stress reduction techniques are helpful things like relaxation exercises, deep breathing, even just better time management can help people feel less overwhelmed. and exercise.
Aerobic exercise can certainly have a positive effect on mood and anxiety. Probably not a standalone cure for a diagnosed disorder, but definitely supportive,
right? What about things people consume? Caffeine,
alcohol,
key area for counseling.
Welcome to the deep dive. If you're gearing up for the Canadian pharmacy PBC exam, you uh you definitely know how much material there is to cover.
It's a lot.
Yeah, a mountain. So, today we're tackling a big one. Anxiety disorders,
a very common and important topic.
Exactly. And we've really tried to distill a key resource for you. Uh this deep dive is brought to you by Pharma Board Group and it's based on the CTC reference.
Right. We've pulled out the essential therapeutic choices, medication algorithms, those key tables, and you know, practical tips you really need for the exam and for practice.
Think of it as maybe a focused review, helping you feel confident you've got the critical stuff covered in this area.
That's the goal, a concise, clear summary. We know that feeling prepared brings peace of mind, and that's what we want to help with.
And it's so relevant for Canadian pharmacists, isn't it? The numbers are pretty staggering.
They really are. Lifetime prevalence estimates are about what, 31% and maybe 24% of Canadians saying they've actually experienced an anxiety disord. order.
Wow. So, you will see this in practice frequently.
Absolutely. And what's also concerning is that they're often underdiagnosed, undertreated even,
which means there's a real role for pharmacists here.
A huge opportunity. Yeah. To help with recognition, support, guiding patients.
So, it's more than just exam prep. It's about good patient care down the line. Okay. So, what's the roadmap for this deep dive? What are we covering?
Well, we'll start with the basics definitions, DSM5TR classifications, then uh goals of therapy. What investigations might look like. Okay. The main part will be the treatments, non-farmacological and pharmacological options.
We'll also get into special populations, pregnancy, breastfeeding, kids, adolescence,
crucial areas.
Definitely. And we'll wrap up with some practical therapeutic tips you can actually use.
Sounds like a solid plan.
Yeah.
Let's jump right into therapeutic choices then. Uh starting with the non-farmacological side. What about psychoeducation? How important is that?
Oh, it's foundational really empower. ing patients with knowledge about their condition, what it is, treatment options, what makes it worse, how to spot early warning signs,
so they understand what's happening.
Exactly. And pharmacists can point them to great resources like uh Relief or Anxiety Canada, good websites, good info to supplement what you provide.
Makes sense. An informed patient is usually a more engaged patient.
Totally. More likely to stick with the plan, feel more in control.
Okay. What about actual therapies? We hear about C CBT exposure therapy.
Yeah, psychotherapy is a cornerstone for the PBC. The big ones to know are cognitive behavioral therapy, CBT exposure therapy, and mindfulness-based approaches. They've all got strong evidence.
CBT seems to come up a lot.
It does. It helps patients identify and change those unhelpful thought patterns and behaviors. Often considered firstline psychotherapy for many anxiety disorders.
What if someone can't easily get to facetoface therapy? Are there alternatives?
Yes, and this is increasingly important. delivered CBT or ICBT.
ICBT. Yeah.
Yeah. There was a big Cochran review showing it's definitely better than being on a weight list. And interestingly, when it includes the support, it seems pretty comparable to traditional face-to-face CBT for a lot of people.
That's really good to know, especially for accessibility.
Huge benefit for access. Yeah.
What else? Beyond formal therapy, lifestyle things.
Definitely. Stress reduction techniques are helpful things like relaxation exercises, deep breathing, even just better time management can help people feel less overwhelmed. and exercise.
Aerobic exercise can certainly have a positive effect on mood and anxiety. Probably not a standalone cure for a diagnosed disorder, but definitely supportive,
right? What about things people consume? Caffeine,
alcohol,
key area for counseling.
Reducing or at least monitoring caffeine and other stimulants is important. They can really ramp up anxiety symptoms.
And alcohol, some people might use it to cope.
Yeah, but it's a tricky one. It can actually worsen anxiety in the long run. And it really messes with sleep quality. So, minimizing or avoiding it as a coping tool is crucial. Plus, withdrawal itself can cause anxiety.
The bad cycle. What about elicit drugs?
Big no. No. Things like cannabis, cocaine, hallucinagens, even anabolic steroids. They can all trigger or worsen anxiety, they really should be stopped.
And if someone's struggling to stop,
referral to addiction services is the way to go. And underlying all this is just, you know, emphasizing a balanced lifestyle, healthy sleep habits, sleep and anxiety are so tight. linked.
Okay. So, a real whole person approach needed on the non-farma side. Let's switch gears to medications. Pharmacologic treatments. When do we usually start thinking about meds?
Generally reserved for moderate to severe anxiety disorders, especially when symptoms are really interfering with daily life, quality of life, or you know, if non-drug approaches just haven't been enough.
And the main players here, the go-to drug classes,
uh, the selective serotonin reuptake inhibitors, SSRIs, and the serotonin Epinephrine reuptake inhibitors, the SNRIs, those are generally your first line choices.
Why them compared to older ones like TCAs?
Mostly tolerability and safety. They just tend to have a better side effect profile and are safer in overdose compared to say the triccyclic anti-depressants or the MAO inhibitors.
Got it. Are the doses for anxiety similar to depression doses?
Generally, yes. The target doses often overlap, but the key difference is how you start. For anxiety, you really want to start low and go slow.
Start low. so slow. Why is that?
To improve tolerability, titrate up gradually, maybe every week or two, until you hit that target dose. Helps minimize those initial side effects that can sometimes feel like increased anxiety,
right? And what's the most important thing to tell patients about when these meds will start working for anxiety.
This is absolutely critical for adherence. They need to understand it takes time. It's not like taking a painkiller.
Not instant relief.
Not at all. It can take anywhere from, say, 2 to 8 weeks to really start feeling the benefits. Sometimes longer, maybe 8 to 12 weeks for the optimal response.
Wow, that's a long time. Dentrol,
it is. And crucially, they might get side effects before they feel better. So setting those realistic expectations right from the start is vital. Otherwise, they might just stop taking it too soon.
That makes sense. What if someone tries one, say an SSRI, gives it a good shot, adequate dose, enough time, and nothing or not enough improvement?
Good question. If there isn't a significant response, and we often look for at least maybe 50% improvement on a standard anxiety scale. The usual next step is to switch to a different anti-depressant.
Switch rather than add something on.
Generally, yes, switch first. Could be another SSRI or maybe switch to an SNRI. Sometimes people respond to one but not another even within the same class. Augmentation, adding another drug usually comes later if needed.
Okay. And how long do people typically stay on these once they are working?
Good question. For relapse prevention, after someone's achieved remission or significant improvement. The recommendation is usually at least 12 to 24 months of continued treatment.
A year or two.
Yeah. And when it's time to stop, it absolutely has to be tapered gradually over several months. Usually stopping abruptly can cause withdrawal symptoms and anxiety can bounce back.
Super important counseling point. What about safety warnings, particularly for younger people?
Yes, very important. Health Canada has warnings about a potential increased risk of suicidal thoughts and behavior in patients under 18 taking anti-depressants.
Under eight,
And alcohol, some people might use it to cope.
Yeah, but it's a tricky one. It can actually worsen anxiety in the long run. And it really messes with sleep quality. So, minimizing or avoiding it as a coping tool is crucial. Plus, withdrawal itself can cause anxiety.
The bad cycle. What about elicit drugs?
Big no. No. Things like cannabis, cocaine, hallucinagens, even anabolic steroids. They can all trigger or worsen anxiety, they really should be stopped.
And if someone's struggling to stop,
referral to addiction services is the way to go. And underlying all this is just, you know, emphasizing a balanced lifestyle, healthy sleep habits, sleep and anxiety are so tight. linked.
Okay. So, a real whole person approach needed on the non-farma side. Let's switch gears to medications. Pharmacologic treatments. When do we usually start thinking about meds?
Generally reserved for moderate to severe anxiety disorders, especially when symptoms are really interfering with daily life, quality of life, or you know, if non-drug approaches just haven't been enough.
And the main players here, the go-to drug classes,
uh, the selective serotonin reuptake inhibitors, SSRIs, and the serotonin Epinephrine reuptake inhibitors, the SNRIs, those are generally your first line choices.
Why them compared to older ones like TCAs?
Mostly tolerability and safety. They just tend to have a better side effect profile and are safer in overdose compared to say the triccyclic anti-depressants or the MAO inhibitors.
Got it. Are the doses for anxiety similar to depression doses?
Generally, yes. The target doses often overlap, but the key difference is how you start. For anxiety, you really want to start low and go slow.
Start low. so slow. Why is that?
To improve tolerability, titrate up gradually, maybe every week or two, until you hit that target dose. Helps minimize those initial side effects that can sometimes feel like increased anxiety,
right? And what's the most important thing to tell patients about when these meds will start working for anxiety.
This is absolutely critical for adherence. They need to understand it takes time. It's not like taking a painkiller.
Not instant relief.
Not at all. It can take anywhere from, say, 2 to 8 weeks to really start feeling the benefits. Sometimes longer, maybe 8 to 12 weeks for the optimal response.
Wow, that's a long time. Dentrol,
it is. And crucially, they might get side effects before they feel better. So setting those realistic expectations right from the start is vital. Otherwise, they might just stop taking it too soon.
That makes sense. What if someone tries one, say an SSRI, gives it a good shot, adequate dose, enough time, and nothing or not enough improvement?
Good question. If there isn't a significant response, and we often look for at least maybe 50% improvement on a standard anxiety scale. The usual next step is to switch to a different anti-depressant.
Switch rather than add something on.
Generally, yes, switch first. Could be another SSRI or maybe switch to an SNRI. Sometimes people respond to one but not another even within the same class. Augmentation, adding another drug usually comes later if needed.
Okay. And how long do people typically stay on these once they are working?
Good question. For relapse prevention, after someone's achieved remission or significant improvement. The recommendation is usually at least 12 to 24 months of continued treatment.
A year or two.
Yeah. And when it's time to stop, it absolutely has to be tapered gradually over several months. Usually stopping abruptly can cause withdrawal symptoms and anxiety can bounce back.
Super important counseling point. What about safety warnings, particularly for younger people?
Yes, very important. Health Canada has warnings about a potential increased risk of suicidal thoughts and behavior in patients under 18 taking anti-depressants.
Under eight,
right? So, But while these meds are still used and can be very helpful, they need careful prescribing, close monitoring, strict follow-up in that age group, interestingly, that risk doesn't seem to apply to adults.
No increased risk in adults.
Doesn't seem so. And some data even hints at a possible protective effect in adults. But still, monitoring for mood changes is always wise across all ages.
Okay. What about benzoazipines? We hear about Valium, Activon. Where do they fit in?
Uh, benzo. They work fast, very effective for acute anxiety, panic attacks, agitation. They can be useful initially when starting an anti-depressant, kind of bridging that gap until the SSRI kicks in.
There's always a butt with benzo, isn't there?
There is big butts. Risks of abuse, sedation, thinking problems, dependence, withdrawal issues, and falls, especially in the elderly,
right?
So, because of all that, they're considered second line, best used short-term if possible, and generally avoided in anyone with a history of substance use problems.
Okay? Second line, short-term. Are there other medication options besides SSIS and benzo?
Yeah, a few others. Things like pregabalin and gabapentin. Their calcium channel modulators have shown some effect in some studies.
Pregabin
lica, right? But there are growing concerns about misuse potential, especially with pregablin and particularly in people with substance use history. Definitely avoid pregablin if someone has current or past opioid use disorder.
Good point.
Any others? Well, there's less strong evidence for agents like Busperone, Martazipene, Velazadone, hydroxazine, trazadone. Some antiscychotics or anti-vulsants might be used as add-ons in really tough treatment resistant cases, but side effects are often limiting.
So, it sounds like the best choice really depends on the specific type of anxiety disorder someone has.
Exactly. The evidence base and even remission rates can differ. Panic disorder, for instance, often responds well to treatment. GAD that starts in adolescence can be more chronic. Separation anxiety often fades in adulthood.
And Thinking about therapy versus meds is one generally seen as better overall.
It's a good question. The evidence suggests both psychotherapy, especially CBT, and medications are effective for most anxiety disorders. Their overall effectiveness is often comparable.
Comparable.
Yeah. Some big analyses, meta analyses, might show a slightly larger average effect size for meds, but it's close. Interestingly, combining them doesn't always yield better results initially for all disorders. Oh, how so?
Well, for example, for GAD, starting with both meds and therapy isn't strongly supported right off the bat. But for panic disorder, combination therapy often works better than therapy alone. It varies.
When would medication definitely be the preferred starting point?
Usually, when symptoms are really severe, significantly impairing function or especially if there's any suicidal thinking. Also, in cases that haven't responded to other approaches, treatment resistant anxiety, that's when a psychiatric consult is definitely needed to.
Okay. Okay, let's get into those specifics then. Starting with panic disorder. What meds work best here?
Right. And remember a lot of the studies mix panic disorder with or without agorophobia. So panic disorder those recurrent unexpected attacks and the fear of having more. Yeah.
For meds SSRI are first line. Cityloperm, acetylop, fluxine, fluoxamine, peroxitine, certuline all have evidence and the SNR venaxine too. No SSRI seems clearly better than others.
What about older drugs?
TCAs like omipramine and clom premine work. similar efficacy actually but they're second line because of side effects and overdose danger. Benzoazipines, Alrazolum, Clinosipam, Laurasipam, Dasipam also second line mostly for short-term or initial use.
Any preference among the benzos?
Clinopam and Laurazipam are often preferred over alprazilam and dasipam.
No increased risk in adults.
Doesn't seem so. And some data even hints at a possible protective effect in adults. But still, monitoring for mood changes is always wise across all ages.
Okay. What about benzoazipines? We hear about Valium, Activon. Where do they fit in?
Uh, benzo. They work fast, very effective for acute anxiety, panic attacks, agitation. They can be useful initially when starting an anti-depressant, kind of bridging that gap until the SSRI kicks in.
There's always a butt with benzo, isn't there?
There is big butts. Risks of abuse, sedation, thinking problems, dependence, withdrawal issues, and falls, especially in the elderly,
right?
So, because of all that, they're considered second line, best used short-term if possible, and generally avoided in anyone with a history of substance use problems.
Okay? Second line, short-term. Are there other medication options besides SSIS and benzo?
Yeah, a few others. Things like pregabalin and gabapentin. Their calcium channel modulators have shown some effect in some studies.
Pregabin
lica, right? But there are growing concerns about misuse potential, especially with pregablin and particularly in people with substance use history. Definitely avoid pregablin if someone has current or past opioid use disorder.
Good point.
Any others? Well, there's less strong evidence for agents like Busperone, Martazipene, Velazadone, hydroxazine, trazadone. Some antiscychotics or anti-vulsants might be used as add-ons in really tough treatment resistant cases, but side effects are often limiting.
So, it sounds like the best choice really depends on the specific type of anxiety disorder someone has.
Exactly. The evidence base and even remission rates can differ. Panic disorder, for instance, often responds well to treatment. GAD that starts in adolescence can be more chronic. Separation anxiety often fades in adulthood.
And Thinking about therapy versus meds is one generally seen as better overall.
It's a good question. The evidence suggests both psychotherapy, especially CBT, and medications are effective for most anxiety disorders. Their overall effectiveness is often comparable.
Comparable.
Yeah. Some big analyses, meta analyses, might show a slightly larger average effect size for meds, but it's close. Interestingly, combining them doesn't always yield better results initially for all disorders. Oh, how so?
Well, for example, for GAD, starting with both meds and therapy isn't strongly supported right off the bat. But for panic disorder, combination therapy often works better than therapy alone. It varies.
When would medication definitely be the preferred starting point?
Usually, when symptoms are really severe, significantly impairing function or especially if there's any suicidal thinking. Also, in cases that haven't responded to other approaches, treatment resistant anxiety, that's when a psychiatric consult is definitely needed to.
Okay. Okay, let's get into those specifics then. Starting with panic disorder. What meds work best here?
Right. And remember a lot of the studies mix panic disorder with or without agorophobia. So panic disorder those recurrent unexpected attacks and the fear of having more. Yeah.
For meds SSRI are first line. Cityloperm, acetylop, fluxine, fluoxamine, peroxitine, certuline all have evidence and the SNR venaxine too. No SSRI seems clearly better than others.
What about older drugs?
TCAs like omipramine and clom premine work. similar efficacy actually but they're second line because of side effects and overdose danger. Benzoazipines, Alrazolum, Clinosipam, Laurasipam, Dasipam also second line mostly for short-term or initial use.
Any preference among the benzos?
Clinopam and Laurazipam are often preferred over alprazilam and dasipam.
Alprazoleum Xanax seems to have a higher risk of rebound anxiety and tricky withdrawal.
Okay. And third one,
dipopramine and phenylene and MAOI are way down the list due to limited data or side effects and restrictions. and things like mortazzipene, mlobamide, bperone, tresidone, propranolol generally not recommended for panic disorder. Uh, table three in the CTC reference summarizes this well.
Great. Table three for panic disorder. Any special tips for starting meds and panic disorder?
Yes, patients with panic disorder can be really sensitive to initial side effects. So that start low, go slow principle, even more important here. Start really low, titrate very slowly.
Got it. What about agorophobia? That fear of situations you can't escape from. Is the medication the same?
Agorophobia? Yeah, that fear of places or situations where escape might be tough if panic hits. Pharmacologically, the treatment is basically the same as for panic disorder, but the core issue in agorophobia is often the avoidance behavior. And medication isn't always great at tackling avoidance. That's where CBT, especially exposure therapy, really shines for agorophobia.
Makes sense. Okay, moving on to social anxiety disorder or social phobia. Fear of being judged first line. meds
again SSRIs and SNRIs are the treatment of choice. Essatalopram, fluoxane, peroxitine, certuline and venlaxine have good evidence. Fluoxitine's data is a bit more mixed for social anxiety.
What about the second line?
Pregobland is an option. It can work especially at higher doses but more side effects and anti-depressants might be better if there's also depression. Benzo like clonosopam, brisopam also second line. Same risks as before.
Other second line options
fenneline, citylopram, makabam IDE, Motazipene, Gabapentine. Some have less data though. Ketamine is maybe third line but not widely available and buserone disphenoline seem ineffective here. Check table four in the reference for this one.
Table four. Okay. Anything else for social anxiety like for performance situations, public speaking nerves?
Yes, good point. For that specific performance related anxiety, a low dose of a beta blocker like propranolol or atanol taken maybe an hour beforehand can help manage the physical symptoms. But not for general social anxiety.
No, generally not effective for the broader day-to-day social anxiety. Just for the specific performance situations.
Okay. What about a specific phobias? Fear of spiders, heights, flying. Meds useful there.
Not usually the main treatment. Specific phobias are really best treated with exposure therapy. That's the gold standard.
So meds rarely needed.
Rarely as a primary treatment. Some studies suggest maybe taking a short acting benzo like alpresolam or pregabbolin before a plant exposure session could potenti help some people manage the anticipatory dread and one study showed fluoxitine might help but really exposure therapy is key.
Got it. Therapy first for specific phobias. Lastly, let's cover generalized anxiety disorder, GAD. That excessive worry about everything.
Yeah, GAD. That constant uncontrollable worry about everyday things lasting 6 months or more. CT is highly effective here on the therapy side
and pharmacologically. First line
SSRIs and SNRIs again is Opram, peroxitine, certillene, benlaxine, deluxitine, citilloprim also has good data specifically in older emeralds with GA
my second line options for GA
a few validone but less long-term data brigaboline keeping the abuse risk in mind benzoazipene same limitations perman the TCA but side effects even bopropene showed promise in one study compared to a satellopram
any third line option
quacapine XR an antiscychotic can work as monotherapy and reduces symptoms quickly but sedation weight gain metabolic issues are significant downsides.
What about things like hydroxazine or busperone?
Hydroxazine worked in one trial but isn't used much clinically because of side effects. Trazadone valpro have limited evidence.
Okay. And third one,
dipopramine and phenylene and MAOI are way down the list due to limited data or side effects and restrictions. and things like mortazzipene, mlobamide, bperone, tresidone, propranolol generally not recommended for panic disorder. Uh, table three in the CTC reference summarizes this well.
Great. Table three for panic disorder. Any special tips for starting meds and panic disorder?
Yes, patients with panic disorder can be really sensitive to initial side effects. So that start low, go slow principle, even more important here. Start really low, titrate very slowly.
Got it. What about agorophobia? That fear of situations you can't escape from. Is the medication the same?
Agorophobia? Yeah, that fear of places or situations where escape might be tough if panic hits. Pharmacologically, the treatment is basically the same as for panic disorder, but the core issue in agorophobia is often the avoidance behavior. And medication isn't always great at tackling avoidance. That's where CBT, especially exposure therapy, really shines for agorophobia.
Makes sense. Okay, moving on to social anxiety disorder or social phobia. Fear of being judged first line. meds
again SSRIs and SNRIs are the treatment of choice. Essatalopram, fluoxane, peroxitine, certuline and venlaxine have good evidence. Fluoxitine's data is a bit more mixed for social anxiety.
What about the second line?
Pregobland is an option. It can work especially at higher doses but more side effects and anti-depressants might be better if there's also depression. Benzo like clonosopam, brisopam also second line. Same risks as before.
Other second line options
fenneline, citylopram, makabam IDE, Motazipene, Gabapentine. Some have less data though. Ketamine is maybe third line but not widely available and buserone disphenoline seem ineffective here. Check table four in the reference for this one.
Table four. Okay. Anything else for social anxiety like for performance situations, public speaking nerves?
Yes, good point. For that specific performance related anxiety, a low dose of a beta blocker like propranolol or atanol taken maybe an hour beforehand can help manage the physical symptoms. But not for general social anxiety.
No, generally not effective for the broader day-to-day social anxiety. Just for the specific performance situations.
Okay. What about a specific phobias? Fear of spiders, heights, flying. Meds useful there.
Not usually the main treatment. Specific phobias are really best treated with exposure therapy. That's the gold standard.
So meds rarely needed.
Rarely as a primary treatment. Some studies suggest maybe taking a short acting benzo like alpresolam or pregabbolin before a plant exposure session could potenti help some people manage the anticipatory dread and one study showed fluoxitine might help but really exposure therapy is key.
Got it. Therapy first for specific phobias. Lastly, let's cover generalized anxiety disorder, GAD. That excessive worry about everything.
Yeah, GAD. That constant uncontrollable worry about everyday things lasting 6 months or more. CT is highly effective here on the therapy side
and pharmacologically. First line
SSRIs and SNRIs again is Opram, peroxitine, certillene, benlaxine, deluxitine, citilloprim also has good data specifically in older emeralds with GA
my second line options for GA
a few validone but less long-term data brigaboline keeping the abuse risk in mind benzoazipene same limitations perman the TCA but side effects even bopropene showed promise in one study compared to a satellopram
any third line option
quacapine XR an antiscychotic can work as monotherapy and reduces symptoms quickly but sedation weight gain metabolic issues are significant downsides.
What about things like hydroxazine or busperone?
Hydroxazine worked in one trial but isn't used much clinically because of side effects. Trazadone valpro have limited evidence.
Busperone is comparable maybe to benzo but slow onset limited long-term data so not used that often. SGAAs like alanzipene might be added in refractory cases but again side effects. Table five summarizes GA meds.
Table five for GAD. Excellent. Now shifting to really crucial are is for pharmacists, special populations, pregnancy and breastfeeding. This comes up all the time.
Absolutely critical. Anxiety disorders are common during pregnancy and postpartum maybe 15 20%. And untreated anxiety isn't good for mom or baby.
So screening is important.
Definitely. Preconception during pregnancy postpartum. For mild to moderate anxiety, therapy like CBT or IBT is first line. Relaxation techniques can help too. Severe symptoms might need meds, possibly referral to psychiatry.
Okay. What are the risks with meds during pregnancy? SSRI. It's complex. First trimester SSRI use might slightly increase spontaneous abortion risk. Peroxitine is generally avoided due to a potential link with cardiac issues in the baby.
Avoid peroxitine in pregnancy.
Got it. Yeah. Third trimester use of SSRIs can lead to a temporary neonatal behavioral syndrome than jitteriness, feeding issues. Peroxitine and fluoxitine might be more associated with this. Autism risk data is unclear, contradictory.
What about SNR? surprise
less data but no clear signal for major malf for still a risk of that neonatal syndrome in the third trimester though
and benzoazipines in pregnancy
generally not linked to major malf formations overall but best to avoid in the first trimester if possible due to some conflicting older data there might be increased risks of other paranatal issues but confounding factors are possible avoid using multiple meds if you can
so the bottom line for severe symptoms
for severe symptoms where maternal or fetal safety is compromised SSRI S NRIs or maybe benzo might be needed. Lowest effective dose is key. If someone was stable on an anti-depressant before pregnancy, often best to continue it.
And if starting one during pregnancy,
citoprillene are often preferred choices based on safety data. Avoid peroxitine.
What about breastfeeding?
Again, non-drug options first if possible. If meds are needed, SSRIs like peroxitine and certuline are often considered preferred because they seem to pass into breast milk in a very low amount. Benzo while breastfeeding
generally best avoided if possible. They can accumulate in the infant, cause sedation, problems with temperature regulation. Always check up-to-date resources for pregnancy and lactation safety.
Absolutely. Okay. What about treating anxiety in children and adolescence?
Yeah, another important group. While some fears are normal in childhood, actual anxiety disorders are common. Maybe 20 30% lifetime prevalence reported in the US. Average onset around age 11
and treated anxiety in kids that can cause problems later,
big problems, impaired development, risk of other psychiatric issues later, even increased risk of suicidal thoughts or behavior, especially if depression is also present.
So, treatment is important. What's first line for kids?
For ages 6 to 18, mild to moderate anxiety, CBT is first line.
Therapy first.
Yes. For more severe cases, or if CBT isn't available, SSRIs or possibly SNRIs are considered. Sometimes combination therapy works best. SSRIs have the best evidence in kids.
Fluoxitine, fluoxamin, peroxitine, certuline have the most data, but and this is crucial, none are officially indicated for anxiety in kids, adolescence in Canada or the US and they all carry that warning about potential increased suicidal thinking behavior risk.
The Health Canada warning applies up to age 18.
Yes, up to 18 in Canada, up to 24 in the US. So careful assessment, psycho education for the child and parents, and close monitoring are absolutely essential if using these meds.
What about SNRIs in kids?
Less data. Delloxitine and Venlaxine have the most. Delloxitine actually has a US indication for GAD in ages 717.
Table five for GAD. Excellent. Now shifting to really crucial are is for pharmacists, special populations, pregnancy and breastfeeding. This comes up all the time.
Absolutely critical. Anxiety disorders are common during pregnancy and postpartum maybe 15 20%. And untreated anxiety isn't good for mom or baby.
So screening is important.
Definitely. Preconception during pregnancy postpartum. For mild to moderate anxiety, therapy like CBT or IBT is first line. Relaxation techniques can help too. Severe symptoms might need meds, possibly referral to psychiatry.
Okay. What are the risks with meds during pregnancy? SSRI. It's complex. First trimester SSRI use might slightly increase spontaneous abortion risk. Peroxitine is generally avoided due to a potential link with cardiac issues in the baby.
Avoid peroxitine in pregnancy.
Got it. Yeah. Third trimester use of SSRIs can lead to a temporary neonatal behavioral syndrome than jitteriness, feeding issues. Peroxitine and fluoxitine might be more associated with this. Autism risk data is unclear, contradictory.
What about SNR? surprise
less data but no clear signal for major malf for still a risk of that neonatal syndrome in the third trimester though
and benzoazipines in pregnancy
generally not linked to major malf formations overall but best to avoid in the first trimester if possible due to some conflicting older data there might be increased risks of other paranatal issues but confounding factors are possible avoid using multiple meds if you can
so the bottom line for severe symptoms
for severe symptoms where maternal or fetal safety is compromised SSRI S NRIs or maybe benzo might be needed. Lowest effective dose is key. If someone was stable on an anti-depressant before pregnancy, often best to continue it.
And if starting one during pregnancy,
citoprillene are often preferred choices based on safety data. Avoid peroxitine.
What about breastfeeding?
Again, non-drug options first if possible. If meds are needed, SSRIs like peroxitine and certuline are often considered preferred because they seem to pass into breast milk in a very low amount. Benzo while breastfeeding
generally best avoided if possible. They can accumulate in the infant, cause sedation, problems with temperature regulation. Always check up-to-date resources for pregnancy and lactation safety.
Absolutely. Okay. What about treating anxiety in children and adolescence?
Yeah, another important group. While some fears are normal in childhood, actual anxiety disorders are common. Maybe 20 30% lifetime prevalence reported in the US. Average onset around age 11
and treated anxiety in kids that can cause problems later,
big problems, impaired development, risk of other psychiatric issues later, even increased risk of suicidal thoughts or behavior, especially if depression is also present.
So, treatment is important. What's first line for kids?
For ages 6 to 18, mild to moderate anxiety, CBT is first line.
Therapy first.
Yes. For more severe cases, or if CBT isn't available, SSRIs or possibly SNRIs are considered. Sometimes combination therapy works best. SSRIs have the best evidence in kids.
Fluoxitine, fluoxamin, peroxitine, certuline have the most data, but and this is crucial, none are officially indicated for anxiety in kids, adolescence in Canada or the US and they all carry that warning about potential increased suicidal thinking behavior risk.
The Health Canada warning applies up to age 18.
Yes, up to 18 in Canada, up to 24 in the US. So careful assessment, psycho education for the child and parents, and close monitoring are absolutely essential if using these meds.
What about SNRIs in kids?
Less data. Delloxitine and Venlaxine have the most. Delloxitine actually has a US indication for GAD in ages 717.
Venlaxine needs extra caution due to potential higher suicide risk and overdose fatality links.
Okay, lots to consider there. Finally, let's wrap up with some quick therapeutic tips for our listeners, things to keep in mind for practice.
Sure. Remember, short-term interventions like relaxation can be useful adjuncts. Short-term benzo use, maybe up to 6, 8 weeks max, can help acutely or anti-depressant initiation.
Don't judge effectiveness too early.
Exactly. Assess effectiveness only after an adequate dose and duration. Using those self-report scales can help track progress objectively.
And if the first drug doesn't work,
switch to another firstline agent if ineffective or not tolerated. Augmentation comes later for partial response to an optimal dose, usually with specialist input.
Great summary. This has been really comprehensive, super helpful for PEBC candidates. And remember everyone, you can refer back to those table 3, four, and five and the algorithms in the CTC reference for quick reviews.
Definitely keep those handy and always stay updated with current guidelines.
Okay, time for our quick quiz question based on today's deep dive. Which of the following SSRIs is generally avoided during pregnancy due to a potential association with congenital cardiac abnormalities? Is it a certuline, b acetalopram, c per proxitine or d fluxine?
Thinking back to our discussion, the answer is c peroxitine.
Correct. Proxitine is the one to generally avoid in pregnancy due to that potential cardiac link. Well, this deep dive into anxiety disorders for Canadian pharmacy PBC candidates was brought to you by Pharma Board Group based on the CTC reference. Thanks so much for tuning in.
Yeah, thanks for joining us. Hope it was helpful.
Definitely check out further resources and guidelines for the full picture and to leave you with something to think about considering just how common anxiety disorders are and their impact. How can you as a future pharmacist proactively contribute to earlier recognition and better management right there in your daily practice?
Okay, lots to consider there. Finally, let's wrap up with some quick therapeutic tips for our listeners, things to keep in mind for practice.
Sure. Remember, short-term interventions like relaxation can be useful adjuncts. Short-term benzo use, maybe up to 6, 8 weeks max, can help acutely or anti-depressant initiation.
Don't judge effectiveness too early.
Exactly. Assess effectiveness only after an adequate dose and duration. Using those self-report scales can help track progress objectively.
And if the first drug doesn't work,
switch to another firstline agent if ineffective or not tolerated. Augmentation comes later for partial response to an optimal dose, usually with specialist input.
Great summary. This has been really comprehensive, super helpful for PEBC candidates. And remember everyone, you can refer back to those table 3, four, and five and the algorithms in the CTC reference for quick reviews.
Definitely keep those handy and always stay updated with current guidelines.
Okay, time for our quick quiz question based on today's deep dive. Which of the following SSRIs is generally avoided during pregnancy due to a potential association with congenital cardiac abnormalities? Is it a certuline, b acetalopram, c per proxitine or d fluxine?
Thinking back to our discussion, the answer is c peroxitine.
Correct. Proxitine is the one to generally avoid in pregnancy due to that potential cardiac link. Well, this deep dive into anxiety disorders for Canadian pharmacy PBC candidates was brought to you by Pharma Board Group based on the CTC reference. Thanks so much for tuning in.
Yeah, thanks for joining us. Hope it was helpful.
Definitely check out further resources and guidelines for the full picture and to leave you with something to think about considering just how common anxiety disorders are and their impact. How can you as a future pharmacist proactively contribute to earlier recognition and better management right there in your daily practice?
اختلال وسواس جبری
Welcome to the deep dive. Today we're tackling obsessivecompulsive disorder, OCD. And I for those of you gearing up for the Canadian pharmacist PBC exam, really understanding the therapeutic choices here is well, it's critical.
Absolutely. And this deep dive comes to you from the Pharma Board Group using the CTC reference as our guide. Our mission today is basically to pull out the must know info on treatments, those medication algorithms, the tables, all the essential tips for OCD management. Think of this as your focused guide. We want to give you that clarity, the accuracy, and you know, the practical insights you'll need not just for the exam, but for practice, too. It should hopefully provide some peace of mind.
Definitely. So, let's dive in. Therapeutic choices for OCD. Where do we begin?
Okay, so the foundations, what are the first line options?
Well, the evidence is really solid for two main approaches.
Specialized cognitive behavioral therapy or CBT and farmotherapy, specifically with SSRI, selective serotonin reuptake inhibitors.
Right. Both strong ly backed by research.
Exactly. High quality studies support both.
But um I gather CBT, the specialized kind, is often seen as the preferred starting point for most. Why is that?
Yeah, that's generally true. The main reason is the risk of relapse when medication is stopped. SSRIs work, no doubt, but stopping them often leads to symptoms returning. Specialized CDT aims for more lasting change.
So it equips patients, but as longterm
precisely, especially exposure and resp response prevention, ERP. That's the core of specialized CBT for OCD. It helps break that cycle of obsessions and compulsions.
That makes a lot of sense. But, you know, finding a therapist who really specializes in OCD, CBT, that can be tough, right? Access is an issue.
It absolutely can be. And that's why starting with an anti-depressant like an SSRI while someone is waiting to get into specialized CBT is seen as a pretty reasonable approach. It bridges that gap.
Okay. A practical step then. And I see there's work being done on setting standards for therapists doing this work?
Yes. Developing knowledge and competency standards. It's important to ensure quality specialized care.
Now, with the medications, how do we know if they're actually working effectively? Is there a specific measure?
Yeah.
In the drug trials, yeah, a clinically meaningful response is usually defined as getting at least a 30% reduction on the YBOCS score. That's the Yale Brown obsessive compulsive scale.
30% reduction.
But interestingly, in the CBT world, there's more talk now about um achieving wellness and recovery, like getting scores down. into the range you'd see in the general population.
A higher bar in a way. Let's dig into that specialized CBT a bit more. ERP, how is it different from the CBT someone might get for say general anxiety?
That's a great question. Specialized CDT for OCD, particularly ERP, is very specifically focused. It involves helping the person gradually face their feared thoughts or situations, the exposure part, and crucially resist performing the compulsive rituals, the response prevention part.
So, it's very targeted. very behavioral.
Exactly. It's not just about challenging thoughts like in some other CBTs. It's about directly confronting the fear and breaking the ritualistic behavior cycle.
And the results seem pretty good.
They do. Meta analyses show something like 65% of patients getting substantial symptom reduction. We're talking an average of 50% improvement at around 15 months.
Wow. Okay. And remission rates
also encouraging. Around 59% right after treatment, which takes maybe 14 15 weeks on average, and still holding at about 57 % at that 15-month follow-up.
That's impressive. But it's not always just ERP, is it? Sometimes more is needed.
That's right. Some individuals have more complex issues like uh metacognitive problems, problematic beliefs about their thoughts. They might need extra cognitive therapy techniques added on.
Welcome to the deep dive. Today we're tackling obsessivecompulsive disorder, OCD. And I for those of you gearing up for the Canadian pharmacist PBC exam, really understanding the therapeutic choices here is well, it's critical.
Absolutely. And this deep dive comes to you from the Pharma Board Group using the CTC reference as our guide. Our mission today is basically to pull out the must know info on treatments, those medication algorithms, the tables, all the essential tips for OCD management. Think of this as your focused guide. We want to give you that clarity, the accuracy, and you know, the practical insights you'll need not just for the exam, but for practice, too. It should hopefully provide some peace of mind.
Definitely. So, let's dive in. Therapeutic choices for OCD. Where do we begin?
Okay, so the foundations, what are the first line options?
Well, the evidence is really solid for two main approaches.
Specialized cognitive behavioral therapy or CBT and farmotherapy, specifically with SSRI, selective serotonin reuptake inhibitors.
Right. Both strong ly backed by research.
Exactly. High quality studies support both.
But um I gather CBT, the specialized kind, is often seen as the preferred starting point for most. Why is that?
Yeah, that's generally true. The main reason is the risk of relapse when medication is stopped. SSRIs work, no doubt, but stopping them often leads to symptoms returning. Specialized CDT aims for more lasting change.
So it equips patients, but as longterm
precisely, especially exposure and resp response prevention, ERP. That's the core of specialized CBT for OCD. It helps break that cycle of obsessions and compulsions.
That makes a lot of sense. But, you know, finding a therapist who really specializes in OCD, CBT, that can be tough, right? Access is an issue.
It absolutely can be. And that's why starting with an anti-depressant like an SSRI while someone is waiting to get into specialized CBT is seen as a pretty reasonable approach. It bridges that gap.
Okay. A practical step then. And I see there's work being done on setting standards for therapists doing this work?
Yes. Developing knowledge and competency standards. It's important to ensure quality specialized care.
Now, with the medications, how do we know if they're actually working effectively? Is there a specific measure?
Yeah.
In the drug trials, yeah, a clinically meaningful response is usually defined as getting at least a 30% reduction on the YBOCS score. That's the Yale Brown obsessive compulsive scale.
30% reduction.
But interestingly, in the CBT world, there's more talk now about um achieving wellness and recovery, like getting scores down. into the range you'd see in the general population.
A higher bar in a way. Let's dig into that specialized CBT a bit more. ERP, how is it different from the CBT someone might get for say general anxiety?
That's a great question. Specialized CDT for OCD, particularly ERP, is very specifically focused. It involves helping the person gradually face their feared thoughts or situations, the exposure part, and crucially resist performing the compulsive rituals, the response prevention part.
So, it's very targeted. very behavioral.
Exactly. It's not just about challenging thoughts like in some other CBTs. It's about directly confronting the fear and breaking the ritualistic behavior cycle.
And the results seem pretty good.
They do. Meta analyses show something like 65% of patients getting substantial symptom reduction. We're talking an average of 50% improvement at around 15 months.
Wow. Okay. And remission rates
also encouraging. Around 59% right after treatment, which takes maybe 14 15 weeks on average, and still holding at about 57 % at that 15-month follow-up.
That's impressive. But it's not always just ERP, is it? Sometimes more is needed.
That's right. Some individuals have more complex issues like uh metacognitive problems, problematic beliefs about their thoughts. They might need extra cognitive therapy techniques added on.
Beliefs about thoughts like having this thought is as bad as doing it.
Exactly. That kind of thing. And we're also seeing specialized protocols being developed for different OCD subtypes like contamination fears versus hoarding versus symmetry obsessions. They need slightly different approaches. tailoring the treatment makes sense. And the intensity matters, too.
It can. Yeah. Some people need more frequent sessions or longer ones. Sometimes having the therapists actually assist with ERP practice out in real world, you know, in their home or workplace is key.
Right. Where the triggers actually happen.
Exactly. And specialized OCD centers that offer these more intensive, tailored, longerterm programs often report even better outcomes, higher recovery rates.
So for pharmacists or other professionals in areas maybe without that deep expertise, What's the advice?
The guidance is clear. If you lack expertise, refer to or at least consult with someone who is an expert in specialized CBT for OCD. Get the patient to the right care.
Okay. What about things like guided self-help? Is that a good starting point?
Um, unfortunately, the evidence for lowintensity CBT, like guided self-help, isn't very strong for OCD. It doesn't reliably beat doing nothing.
So, not recommended as a first step.
Not really. Internetbased CBT is showing some promise which is good for access but this idea of stepped care starting with self-help and only moving up if needed that's not evidence-based for OCD there's a real risk of undertreatment maybe even making symptoms worse
that's a really important caution what about related disorders like hoarding or BDB do they have their own CBT
yes they do there are specific evidence-based specialized CBT protocols developed just for those conditions as well
okay now shifting gears a bit what about treatments for people who haven't responded to these first line options, the more experimental stuff,
right? For treatment resistant OCD, there are brain stimulation therapies being looked at. One is RTMS, repetitive transcranial magnetic stimulation. It uses magnetic pulses on the surface of the cortex.
And the results,
some preliminary evidence suggests it might offer benefit for up to about 12 weeks. Then there's DTMS, deep TMS, which can reach deeper brain areas,
deeper stimulation.
Yeah. One trial showed a 45% response rate compared to 18% with a sham treatment. The main side effect seems to be mild headache, which is pretty common.
Okay. And even more invasive options.
There's deep brain stimulation or DBS that involves surgically implanting a device, a neuro stimulator into specific brain regions targeted for OCD.
That sounds quite serious.
It is. Meta analyses show about a 50% response rate in severe treatment resisting cases, which is significant. But full remission, getting completely better, is less common, maybe around 8%. Adverse effects are usually mild. But they are common
and neuroblation making lesions in the brain.
Yes, that's another approach creating small irreversible lesions. Openle label trials show response rates around 54 62%.
But and this is crucial the risk of serious side effects is much higher potentially 5 21%.
So these are really reserved options.
Absolutely reserved for patients who haven't responded to optimized CBT and multiple medication trials. And honestly we still need more rigorous control trials for all these techniques.
Understood. Just to clarify, ECT electrocombulsive therapy that's not for OCD itself.
No, generally not help for OCD symptoms directly.
It's really only considered if someone has severe comorbid depression, for example, where ECT might be used for the mood disorder.
Okay, let's pivot back to pharmarmacothotherapy. Super important for the PBC candidates listening. You mentioned figure 1, table 3, table four in the reference material. Let's break down those firstline drugs from table three, right? The SSRI. So, we're talking about cyolopramopramoxy fluoxamine, peroxitine, and certuline. Those are the go-tos.
Exactly. That kind of thing. And we're also seeing specialized protocols being developed for different OCD subtypes like contamination fears versus hoarding versus symmetry obsessions. They need slightly different approaches. tailoring the treatment makes sense. And the intensity matters, too.
It can. Yeah. Some people need more frequent sessions or longer ones. Sometimes having the therapists actually assist with ERP practice out in real world, you know, in their home or workplace is key.
Right. Where the triggers actually happen.
Exactly. And specialized OCD centers that offer these more intensive, tailored, longerterm programs often report even better outcomes, higher recovery rates.
So for pharmacists or other professionals in areas maybe without that deep expertise, What's the advice?
The guidance is clear. If you lack expertise, refer to or at least consult with someone who is an expert in specialized CBT for OCD. Get the patient to the right care.
Okay. What about things like guided self-help? Is that a good starting point?
Um, unfortunately, the evidence for lowintensity CBT, like guided self-help, isn't very strong for OCD. It doesn't reliably beat doing nothing.
So, not recommended as a first step.
Not really. Internetbased CBT is showing some promise which is good for access but this idea of stepped care starting with self-help and only moving up if needed that's not evidence-based for OCD there's a real risk of undertreatment maybe even making symptoms worse
that's a really important caution what about related disorders like hoarding or BDB do they have their own CBT
yes they do there are specific evidence-based specialized CBT protocols developed just for those conditions as well
okay now shifting gears a bit what about treatments for people who haven't responded to these first line options, the more experimental stuff,
right? For treatment resistant OCD, there are brain stimulation therapies being looked at. One is RTMS, repetitive transcranial magnetic stimulation. It uses magnetic pulses on the surface of the cortex.
And the results,
some preliminary evidence suggests it might offer benefit for up to about 12 weeks. Then there's DTMS, deep TMS, which can reach deeper brain areas,
deeper stimulation.
Yeah. One trial showed a 45% response rate compared to 18% with a sham treatment. The main side effect seems to be mild headache, which is pretty common.
Okay. And even more invasive options.
There's deep brain stimulation or DBS that involves surgically implanting a device, a neuro stimulator into specific brain regions targeted for OCD.
That sounds quite serious.
It is. Meta analyses show about a 50% response rate in severe treatment resisting cases, which is significant. But full remission, getting completely better, is less common, maybe around 8%. Adverse effects are usually mild. But they are common
and neuroblation making lesions in the brain.
Yes, that's another approach creating small irreversible lesions. Openle label trials show response rates around 54 62%.
But and this is crucial the risk of serious side effects is much higher potentially 5 21%.
So these are really reserved options.
Absolutely reserved for patients who haven't responded to optimized CBT and multiple medication trials. And honestly we still need more rigorous control trials for all these techniques.
Understood. Just to clarify, ECT electrocombulsive therapy that's not for OCD itself.
No, generally not help for OCD symptoms directly.
It's really only considered if someone has severe comorbid depression, for example, where ECT might be used for the mood disorder.
Okay, let's pivot back to pharmarmacothotherapy. Super important for the PBC candidates listening. You mentioned figure 1, table 3, table four in the reference material. Let's break down those firstline drugs from table three, right? The SSRI. So, we're talking about cyolopramopramoxy fluoxamine, peroxitine, and certuline. Those are the go-tos.
And the key thing to remember about time frame,
it takes time. You might see about 80% of the benefit within 6 weeks, but you really need to give it up to 12 weeks, maybe even longer sometimes at an adequate dose to see the maximum effect.
12 weeks for a full trial. And what if someone isn't improving much early on, say at 4 weeks?
That's actually a decent predictor.
Yeah.
If there's less than about a 20% improvement on the YBOCs at 4 weeks, the chance of them responding well by 12 weeks drops quite a bit maybe only a 20% chance
okay so that 4-we mark is a point to reassess
definitely whereas if they have shown more than 20% improvement at 4 weeks their chances of responding by 12 weeks jump up to over 50%.
Is any one SSRI clearly better than the others
you know the evidence doesn't really support one being consistently superior across the board for OCD but individuals can respond very differently one person might do great on search lane another might tolerate fluoxitine better or find fluoxamin works best. Tolerability varies too.
And dosage that seems really crucial for OCD, maybe more so than for depression.
Yes, that's a critical point. Higher doses of SSRIs are often needed to get good control of OCD symptoms compared to what you might typically use for depression.
But higher doses mean potentially more side effects.
Exactly. It's always a balance between efficacy and tolerability. The usual approach is start low, maybe for the first week, then gradually increase the dose. You want to get to the maximum tolerated dose and stay there for at least 6 weeks before deciding it's not working or switching.
Maximum tolerated dose for 6 weeks,
right? And sometimes specialists might even carefully push the dose beyond the standard approved maximums with the patients informed consent of course. But you have to be cautious especially thinking about risks like seizures or uh QTC prolongation with citr and esopram at very high doses.
Okay. So if that first SSRI trial even at a good dose for enough time doesn't work out. What are the options then?
Generally, you'd think about three main paths. Switching to a different SSRI, maybe trying that super therapeutic dosing if it wasn't already attempted and seems feasible, or adding something else on augmentation strategies.
Let's talk about switching first. What about other monotherapies, second line choices?
Okay, so second line monotherapy, you're primarily looking at venaxine, which is an SNRI or clomoprain, an older tricyclic antidepressant.
Venlaxine, how does that work?
It inhibits both serotonin and norepinephrine reuptake. Its benefit in OCD is thought to come mainly from the serotonin part. It might be a good option if the patient also has say chronic pain or major depression. Though switching from an SSRI to ventilaxine might sometimes be less effective than just trying another SSRI
and clomopraine.
Clomopraine is actually quite effective similar efficacy to SSRIs. The big issue is tolerability. It has more side effects anticolinergic effects like dry mouth constipation plus sedation from antihistamine effects. And a major concern is that it's dangerous. is an overdose.
Okay, so significant drawbacks there. What about morttazipene?
Mertazzipene, the evidence for it as a standalone treatment for OCD is pretty weak. It might be considered if someone cannot tolerate SSRIs, maybe due to sexual side effects or potentially as an add-on treatment, an augmentation agent, but it often causes weight gain.
Right? So, let's talk more about augmentation. If an SSRI isn't cutting it alone, what gets added?
The agents with the best evidence for augmentation are actually antiscychotics. Specifically, Piprizole and Respperadone. They are dopamine receptor partial agonists or antagonists.
Antiscychotics for OCD.
Yes. Used as augmenting agents. They seem to help maybe around 30% of people who have an inadequate response to SSRIs. You usually titrate them up to a middle dose and check for benefit around the four-week mark.
And side effects to watch for.
it takes time. You might see about 80% of the benefit within 6 weeks, but you really need to give it up to 12 weeks, maybe even longer sometimes at an adequate dose to see the maximum effect.
12 weeks for a full trial. And what if someone isn't improving much early on, say at 4 weeks?
That's actually a decent predictor.
Yeah.
If there's less than about a 20% improvement on the YBOCs at 4 weeks, the chance of them responding well by 12 weeks drops quite a bit maybe only a 20% chance
okay so that 4-we mark is a point to reassess
definitely whereas if they have shown more than 20% improvement at 4 weeks their chances of responding by 12 weeks jump up to over 50%.
Is any one SSRI clearly better than the others
you know the evidence doesn't really support one being consistently superior across the board for OCD but individuals can respond very differently one person might do great on search lane another might tolerate fluoxitine better or find fluoxamin works best. Tolerability varies too.
And dosage that seems really crucial for OCD, maybe more so than for depression.
Yes, that's a critical point. Higher doses of SSRIs are often needed to get good control of OCD symptoms compared to what you might typically use for depression.
But higher doses mean potentially more side effects.
Exactly. It's always a balance between efficacy and tolerability. The usual approach is start low, maybe for the first week, then gradually increase the dose. You want to get to the maximum tolerated dose and stay there for at least 6 weeks before deciding it's not working or switching.
Maximum tolerated dose for 6 weeks,
right? And sometimes specialists might even carefully push the dose beyond the standard approved maximums with the patients informed consent of course. But you have to be cautious especially thinking about risks like seizures or uh QTC prolongation with citr and esopram at very high doses.
Okay. So if that first SSRI trial even at a good dose for enough time doesn't work out. What are the options then?
Generally, you'd think about three main paths. Switching to a different SSRI, maybe trying that super therapeutic dosing if it wasn't already attempted and seems feasible, or adding something else on augmentation strategies.
Let's talk about switching first. What about other monotherapies, second line choices?
Okay, so second line monotherapy, you're primarily looking at venaxine, which is an SNRI or clomoprain, an older tricyclic antidepressant.
Venlaxine, how does that work?
It inhibits both serotonin and norepinephrine reuptake. Its benefit in OCD is thought to come mainly from the serotonin part. It might be a good option if the patient also has say chronic pain or major depression. Though switching from an SSRI to ventilaxine might sometimes be less effective than just trying another SSRI
and clomopraine.
Clomopraine is actually quite effective similar efficacy to SSRIs. The big issue is tolerability. It has more side effects anticolinergic effects like dry mouth constipation plus sedation from antihistamine effects. And a major concern is that it's dangerous. is an overdose.
Okay, so significant drawbacks there. What about morttazipene?
Mertazzipene, the evidence for it as a standalone treatment for OCD is pretty weak. It might be considered if someone cannot tolerate SSRIs, maybe due to sexual side effects or potentially as an add-on treatment, an augmentation agent, but it often causes weight gain.
Right? So, let's talk more about augmentation. If an SSRI isn't cutting it alone, what gets added?
The agents with the best evidence for augmentation are actually antiscychotics. Specifically, Piprizole and Respperadone. They are dopamine receptor partial agonists or antagonists.
Antiscychotics for OCD.
Yes. Used as augmenting agents. They seem to help maybe around 30% of people who have an inadequate response to SSRIs. You usually titrate them up to a middle dose and check for benefit around the four-week mark.
And side effects to watch for.
With these, you need to monitor for things like metabolic syndrome, weight gain, changes in blood sugar or lipids, and potentially movement disorders. though may be less risk with arapiprazil. Olanzipene and quitipene have also been studied but the data supporting them is more mixed.
Okay. And beyond the antiscychotics you mentioned glutamate modulators earlier.
Yes. For more refractory cases if SSRIs plus dopamine antagonists haven't worked or weren't tolerated drugs like lamatrodine meantine to pyramate amantadine adding these onto an SSRI might help some people.
How's the tolerability generally?
Generally they're reasonably well tolerated with the exception of top which can sometimes cause has cognitive side effects or other issues. Lemmitrine and meantine might be common next steps after trying respirone or aeroprizole augmentation
and things like ketamine.
Ketamine is definitely being investigated. Lots of research interest, but it's not really in standard clinical practice for OCD yet.
What about anicylcysteine? I've heard about that.
Yeah, NC. It's a neutrautical. There's some well some mixed but emerging evidence that adding it to serotoninergic meds might be beneficial possibly more for the compulsions needs more study though.
And just to be clear, benzoazipines, lithium,
generally not helpful for the core symptoms of OCD. They might be used if someone has severe coexisting anxiety or mood issues that need managing, but not for the OCD itself.
Okay. So, tracking progress is key. You mentioned the YBOCS.
Yes, the YBOCS is the gold standard. Or sometimes a shorter version like the BOCS is used in clinical practice. You'd ideally use it to monitor response at key points, maybe 4 weeks, 12 weeks. And when Whenever you're making a treatment decision
and if a treatment is successful, how long should it continue?
The general recommendation is for at least a year of continuation treatment after achieving a good response.
A full year. And what about stopping medication?
That's tricky. Relapse rates after stopping medication monotherapy are unfortunately quite high. The decision to stop really needs to be individualized. Usually waiting until the person has been stable psychosoccially for a prolonged period. And if you do stop, Taper the antid-depressant very gradually to minimize discontinuation symptoms and watch closely for any signs of relapse.
It sounds like medication alone often isn't enough to get people fully well.
That's a really important point. Most patients don't reach minimal symptoms with just medication. That's why combining pharmarmacologic treatment with specialized CBT, especially ERP, whenever possible is so crucial. It really optimizes outcomes.
Adding ERP improves things significantly.
Yes. Substantially improves the response rate compared to meds alone. And And it seems to make people less susceptible to relapse later on.
What about people who do CBT first? Can they sometimes come off meds later?
Yes. There's evidence suggesting that individuals who complete successful CBT while on an SRI might be able to maintain their stability even after carefully tapering off the medication with ongoing monitoring of course.
And combination therapy might be particularly helpful for certain folks.
Definitely people who are maybe more treatment resistant, perhaps those with poor insight into their illness. or really strong beliefs about their obsessions, overvalued ideas, or just very high levels of distress, combination therapy can often be beneficial for them.
Okay, let's summarize some of those key therapeutic tips from the guidelines. What are the highlights?
Number one, get specialized CBT started as soon as possible. If someone's on an SSRI and they feel improved or much improved after 6 weeks, keep going for the full 12 weeks. Don't switch too soon.
And if they haven't improved by 6 weeks,
first check adherence. Are they actually taking as prescribed, then consider pushing the dose up to the maximum tolerated level before thinking about switching meds.
Okay. And beyond the antiscychotics you mentioned glutamate modulators earlier.
Yes. For more refractory cases if SSRIs plus dopamine antagonists haven't worked or weren't tolerated drugs like lamatrodine meantine to pyramate amantadine adding these onto an SSRI might help some people.
How's the tolerability generally?
Generally they're reasonably well tolerated with the exception of top which can sometimes cause has cognitive side effects or other issues. Lemmitrine and meantine might be common next steps after trying respirone or aeroprizole augmentation
and things like ketamine.
Ketamine is definitely being investigated. Lots of research interest, but it's not really in standard clinical practice for OCD yet.
What about anicylcysteine? I've heard about that.
Yeah, NC. It's a neutrautical. There's some well some mixed but emerging evidence that adding it to serotoninergic meds might be beneficial possibly more for the compulsions needs more study though.
And just to be clear, benzoazipines, lithium,
generally not helpful for the core symptoms of OCD. They might be used if someone has severe coexisting anxiety or mood issues that need managing, but not for the OCD itself.
Okay. So, tracking progress is key. You mentioned the YBOCS.
Yes, the YBOCS is the gold standard. Or sometimes a shorter version like the BOCS is used in clinical practice. You'd ideally use it to monitor response at key points, maybe 4 weeks, 12 weeks. And when Whenever you're making a treatment decision
and if a treatment is successful, how long should it continue?
The general recommendation is for at least a year of continuation treatment after achieving a good response.
A full year. And what about stopping medication?
That's tricky. Relapse rates after stopping medication monotherapy are unfortunately quite high. The decision to stop really needs to be individualized. Usually waiting until the person has been stable psychosoccially for a prolonged period. And if you do stop, Taper the antid-depressant very gradually to minimize discontinuation symptoms and watch closely for any signs of relapse.
It sounds like medication alone often isn't enough to get people fully well.
That's a really important point. Most patients don't reach minimal symptoms with just medication. That's why combining pharmarmacologic treatment with specialized CBT, especially ERP, whenever possible is so crucial. It really optimizes outcomes.
Adding ERP improves things significantly.
Yes. Substantially improves the response rate compared to meds alone. And And it seems to make people less susceptible to relapse later on.
What about people who do CBT first? Can they sometimes come off meds later?
Yes. There's evidence suggesting that individuals who complete successful CBT while on an SRI might be able to maintain their stability even after carefully tapering off the medication with ongoing monitoring of course.
And combination therapy might be particularly helpful for certain folks.
Definitely people who are maybe more treatment resistant, perhaps those with poor insight into their illness. or really strong beliefs about their obsessions, overvalued ideas, or just very high levels of distress, combination therapy can often be beneficial for them.
Okay, let's summarize some of those key therapeutic tips from the guidelines. What are the highlights?
Number one, get specialized CBT started as soon as possible. If someone's on an SSRI and they feel improved or much improved after 6 weeks, keep going for the full 12 weeks. Don't switch too soon.
And if they haven't improved by 6 weeks,
first check adherence. Are they actually taking as prescribed, then consider pushing the dose up to the maximum tolerated level before thinking about switching meds.